

2021

SOLVENCY
AND FINANCIAL
CONDITION REPORT

VIG **Re**

Table of Content

Summary	4
A – Business and Performance	7
A.1 Business.....	8
A.2 Underwriting Performance.....	11
A.3 Investment Performance.....	16
A.4 Performance of Other Activities.....	18
A.5 Any Other Information.....	18
B – System of Governance	19
B.1 General Information on the System of Governance.....	20
B.2 Fit and Proper Requirements.....	25
B.3 Risk Management System Including the Own Risk and Solvency Assessment.....	26
B.4 Internal Control System.....	34
B.5 Compliance Function.....	35
B.6 Internal Audit Function.....	36
B.7 Actuarial Function.....	37
B.8 Outsourcing.....	38
B.9 Any Other Information.....	39
C – Risk Profile	40
C.1 Underwriting Risk.....	42
C.2 Market Risk.....	48
C.3 Credit Risk.....	52
C.4 Liquidity Risk.....	53
C.5 Operational Risk.....	54
C.6 Other Material Risks.....	55
C.7 Any Other Information.....	55

D – Valuation for Solvency Purposes	56
D.1 Assets.....	57
D.2 Technical Provisions	61
D.3 Other Liabilities.....	70
D.4 Alternative Methods for Valuation	71
D.5 Any Other Information	71
E – Capital Management	72
E.1 Own Funds.....	73
E.2 Solvency Capital Requirement and Minimum Capital Requirement	76
E.3 Use of the Duration-Based Equity Risk Sub-Module in the Calculation of the Solvency Capital Requirement	78
E.4 Differences between the Standard Formula and Any Internal Model Used	78
E.5 Non-Compliance with the Minimum Capital Requirement and Non-Compliance with the Solvency Capital Requirement	81
E.6 Any Other Information.....	81
ABBREVIATIONS	82
LIST OF TABLES	83
LIST OF FIGURES	84
ANNEXES	85
Annex I – Organisational Structure as of 31 December 2021	85
Annex II – Quantitative Information.....	86

Summary

The purpose of Solvency Financial Condition Report (hereinafter “the Report”) is to respond to the public disclosure requirements as defined by the Solvency II Regulation. The elements of the disclosure relate to business performance, governance, risk profile, solvency and capital management.

VIG RE zajišťovna, a.s. (hereinafter also “VIG Re” or “the Company”) is a member of Vienna Insurance Group (“VIG”) and was incorporated on 18 August 2008 after receiving the license to carry out reinsurance business and related activities on 8 August 2008. It has its headquarters at Templová 747/5, Prague 1 and conducts reinsurance business in non-life, life and health lines of business since 2009.

VIG Re is responsible for managing the Group reinsurance programs of Vienna Insurance Group and assumes reinsurance from insurance undertakings outside of VIG Group from Continental Europe and East Asia.

VIG Re adheres to a prudent risk management policy, emphasizing underwriting discipline, a conservative investment policy and comprehensive reinsurance protection. In combination with a strong capital position, its nimble operating model and the ability to offer broad risk solutions across all main lines of business, the Company is well positioned to seize opportunities in its markets.

Business and Performance

In line with the Company strategy, gross written premium increased to EUR 661 million in 2021, a 14% increase compared to 2020. The P&C business segment contributed with EUR 600 million, health with EUR 28 million and Life with EUR 33 million.

In 2021 VIG Re reported a profit before tax of EUR 27 million. The combined ratio for the period was 96.1%, improving by 0.8 percentage points compared to last year. While the gross underwriting result in 2021 was significantly impacted by major natural events in summer 2021 most notably storms Bernd and Volker accounting for gross claims in the amount of almost EUR 336 million, the net loss incurred for VIG Re was EUR 7 million due to a conservative retrocession program in place.

The investment revenues of EUR 8.2 million fully reflect the prudent structure of the assets risk profile. Net gains increased significantly in 2021 mainly due to the sales of collective investments undertakings. Total investment result was negatively affected by EUR 3.2 million loss stemming from FX revaluation of assets held against liabilities in foreign currencies.

The Company's business activities per material lines of business and regions are set out in chapter A.

System of Governance

The Company's system of governance as defined in the internal standards encompasses integral elements, such as an integrated risk management system, the internal control system and the four key functions (actuarial function, compliance function, risk management function, internal audit function).

Continuous improvement of the risk management and steering as well as a high integration of risk considerations in the planning, business and decision-making processes throughout the Company are paramount to VIG Re's Risk Strategy.

An integral element which combines the quantitative and qualitative risk management results and the strategic and business planning is the forward-looking Own Risk and Solvency Assessment (ORSA) as an important element in the integrated planning process and impacting the strategic and business decisions-making in the VIG Re management processes.

Persons who effectively run the Company, key function holders and persons with material impact on the Company's risk profile are fit and proper for their positions. The remuneration system is in accordance with Solvency II Regulation and the Company's business and risk strategy.

Changes to the organizational structure of Supervisory Board and Board of Directors and the overall system of governance during 2021 are commented in chapter B.

Risk Profile

In the context of VIG Re's main activity operating as a reinsurance company, the most significant risk category is underwriting risk. The Company is especially exposed to non-life underwriting risk and to a moderate extent to life and health underwriting risk. Underwriting risk is managed through the adherence to a prudent underwriting policy, including the application of underwriting limits, a strict accumulation control, and is further mitigated by a prudent retrocession program. The Company uses a partial internal model for the non-life underwriting risk and the NSLT health underwriting risk.

Market risk is governed by VIG Re's Investment Strategy which sets a balanced risk/return-profile and limits for asset allocation. To manage counterparty default risk VIG Re distributes its reinsurance protection programs over a diversified panel of financially solid reinsurance companies, in compliance with VIG Security Guidelines. In the area of operational risk, procedures, controls and emergency plans areas are in place to ensure sustainable reinsurance services.

The Solvency Capital Requirement increased from EUR 125 million in 2020 to EUR 156 million in 2021. Most of risk modules increased as a result of the Company's portfolio growth, increased retention in non-life portfolio and further amplified by the nat cat events occurred in summer 2021 which temporarily affected counterparty default risk and operational risk.

Detailed information for VIG Re's risk profile and its key procedures of risk mitigation is provided in chapter C.

Valuation for Solvency Purposes

The valuation of assets and liabilities for Solvency II purposes is performed on a fair value (market value) basis. In case IFRS values appropriately reflect the fair value, these are used for Solvency purposes as well. Chapter D further elaborates on the main differences between statutory reports according to IFRS standards and Solvency II valuation separately for each item. The differences are stemming mainly from technical provisions and reinsurance recoverables as well as from valuation of deposits to cedants and investments (especially held to maturity bond portfolio).

Capital Management

The Company's own funds comprise the ordinary share capital, the share premium, the reconciliation reserve and subordinated liabilities. Eligible own funds amount in 2021 to EUR 270 million, increased by approximately EUR 24 million compared to prior year. The increase stems mainly from the issuance of a perpetual and subordinated certificate of EUR 20 million nominal value qualifying as restricted Tier 1 own funds. The certificate was issued in accordance with the Company's capital planning supporting the strategic growth.

The solvency ratio amounted to 173.5% in 2021, decreased compared to last year as a result of the increased SCR. The solvency ratio includes the foreseeable dividend payment for the financial year 2021 and takes into consideration the full implementation of the new tax law in the Czech Republic which affects the loss-absorbing capacity of deferred taxes since 2020.

The Solvency Financial Condition Report 2021 was approved by the Board of Directors on 6th of April 2022.

It is worth noting that sums and percentages calculations may include minor deviations due to rounding effects.

Russian Ukrainian conflict, as of April 2022

We are continuously monitoring and assessing the development and the associated risks connected with the Russian-Ukrainian conflict that broke out on 24th of February 2022.

In accordance with the international sanctions and adopted laws of the Russian Federation, transactions with Russian counterparties are gradually terminated. For the time of the conflict the Company will not enter any new business in Russian and regarding the existing portfolio steps have already been taken to unwind in force contracts.

For asset and liability management purposes, VIG Re holds one Russian government bond in RUB currency, valued at EUR 2 million as of 31 December 2021 representing less than 0.2% of total assets. Due to the devaluation of RUB currency the value as of 22 March 2022 decreased to EUR 1,5 million. The currency gap in RUB is less than EUR 0.5 million in our Solvency II balance sheet.

The Company's management is not aware of any other event that has occurred since the balance sheet date that would have a material impact on the financial statements.

B U S I N E S S
A N D
P E R F O R M A N C E



A.1 Business

A.1.1 Name and Legal Form of the Undertaking

VIG RE zajišťovna, a.s. is a company incorporated in the Czech Republic in the form of a joint-stock company, registered in the Commercial Register maintained with the Municipal Court in Prague, file no. B 14560 and with identification no. 28445589 (hereinafter the “Company” or “VIG Re”).

The address of the registered office and official webpage is as follows:

Templová 747/5
110 01 Prague 1
Czech Republic

www.vig-re.com

This Report covers VIG Re on a solo basis.

The Company has a licence to pursue the following activities:

- Reinsurance activity under § 3 paragraph 1, lett. (l) of Act No. 277/2009 Coll. Insurance Act, as amended (hereinafter the “Insurance Act”), within all branches of life insurance listed in Appendix 1 of the Insurance Act, Part A and all non-life insurance branches listed in Appendix 1 of the Insurance Act, Part B.
- Activities related to reinsurance activities under the Insurance Act:
 - investigation of reinsurance events;
 - mediation activities undertaken in connection with reinsurance activities;
 - consulting services related to reinsurance;
 - educational activities for reinsurance intermediaries and independent assessors of reinsurance events.

The aforementioned activities were performed by the Company as of the date of this report. Performance of these activities was not limited or suspended by the Czech National Bank during the vesting period.

Underwriting Territories

Figure 1 - Underwriting Territories




Figure 1 shows the underwriting territories from which the Company assumes reinsurance contracts in 2021. These would include most Continental European countries as well as Japan and South Korea. In 2021, the Company extended its reinsurance activities to Norway, Finland, Sweden, Iceland, Denmark, Malta, Greece, Algeria, Morocco, Tunisia and Taiwan.

A.1.2 Name of the Supervisory Authority Responsible for the Financial Supervision of the Undertaking and Group

The Company is subject to supervision by Česká národní banka (Czech National Bank). Česká národní banka can be contacted at:

Na Příkopě 28
115 03 Prague
Czech Republic
www.cnb.cz

The Company is a member of the VIENNA INSURANCE GROUP AG Wiener Versicherung Gruppe which is subject to supervisory authority by the Finanzmarktaufsicht in Österreich (Austrian Financial Market Authority), which can be contacted at:

Otto Wagner Platz 5
1090 Vienna
Austria
www.fma.gv.at

A.1.3 External Auditor of the Undertaking

The statutory auditor of the Company is:

KPMG Česká republika Audit, s.r.o.

Pobřežní 648/1a

186 00 Praha 8

Czech Republic

www.kpmg.cz

A.1.4 Holders of Qualifying Holdings in the Undertaking

Table 1 - Shareholders of the Undertaking

Business Name	Legal Form	Address	Share Capital	Share of Voting Rights
VIENNA INSURANCE GROUP AG Wiener Versicherung Gruppe	joint-stock company	Schottenring 30, 1010 Wien	55%	55%
Donau Versicherung AG Vienna Insurance Group	joint-stock company	Schottenring 15, 1010 Wien	10%	10%
Kooperativa pojišťovna, a.s., Vienna Insurance Group	joint-stock company	Pobřežní 665/21, 186 00 Praha 8	10%	10%
Kooperativa poisťovňa, a.s. Vienna Insurance Group	joint-stock company	Štefanovičova 4, 816 23 Bratislava	10%	10%
WIENER STÄDTISCHE Versicherung AG Vienna Insurance Group	joint-stock company	Schottenring 30, 1010 Wien	15%	15%

A.1.5 Legal Structure

VIG Re is a member of VIENNA INSURANCE GROUP AG Wiener Versicherung Gruppe. Detailed list of related parties is available in the annual report of the Company under Annex 2 to the Report on Related Parties.

In line with its strategic focus on Continental European reinsurance markets, the Company established a branch office in Frankfurt am Main, Germany, in September 2017 and in Paris, France, in November 2018. The economic data of the branches is, in accordance with the legislation of the Czech Republic, an integral part of the financial statements of the Company.

VIG Re has a subsidiary in Wiener Re a.d.o. Serbia, which was acquired from WIENER STÄDTISCHE Versicherung AG Vienna Insurance Group. Wiener Re is a reinsurance company based in Belgrade and is currently active in Serbia and the adjacent countries Bosnia and Herzegovina, Montenegro and Macedonia.

VIG Re has also share in VIG FUND, a.s. The company operates in the area of real estate management.

Table 2 - VIG Re Shares 2021

Business Name	Legal Form	Address	Share Capital	Share of Voting Rights
Wiener Re a.d.o. Serbia	joint-stock company	Trešnjinog cveta 1, 11070 Belgrade	100%	100%
VIG FUND, a.s	joint-stock company	Templová 747/5, 110 00 Praha 1	3.13%	3.13%

Table 3 - VIG Re Shares 2020

Business Name	Legal Form	Address	Share Capital	Share of Voting Rights
Wiener Re a.d.o. Serbia	joint-stock company	Trešnjinog cveta 1, 11070 Belgrade	100%	100%
VIG FUND, a.s	joint-stock company	Templová 747/5, 110 00 Praha 1	2.75%	2.75%

A.2 Underwriting Performance

A.2.1 Underwriting Performance in 2021

Economic Environment

By the end of 2021 optimism was widely prevailing that the global economy will continue on its recovery path from the impacts of the Covid-19 pandemic. National vaccination programs and contingent measures were able to contain the spread of the virus and the public life started to adopt to a “new normal”. Governmental deficit spending as well as fiscal and central bank monetary policy supported the economic recovery. By the end of 2021 new virus variants were regarded as the largest threat to the recovery, leading to a stressed health system and reinforcing partial lock down measures. While by the end of 2021 inflation was hiking up as a consequence of stretched supply chains and rising energy prices, most economist assessed this as a temporary effect, which would ease in the course of the year.

The Russian war on Ukraine in February 2022 however did not only bring hardship and destruction to a large country in Central and Eastern Europe but is likely to have a significant impact on the global economy. The global raise of energy and food prices as immediate effects leads to an even more pronounced inflation. The international sanctions imposed on Russia and the disruption of European supply chains from Ukrainian productions sites will have adverse impacts on the global and even more pronounced on the European economy.

Apart from the increasing risk of stagflation and continued low interest rates, a number of other known risks clearly emerged during the past years, namely more frequent and more severe weather related natural catastrophes caused by climate change, the vulnerability of the global economy to the disruption of supply chains, cyber risks and other risks related to new technologies and digitalisation.

While these risks are a challenge to the industry, they also raise opportunities for an industry whose purpose is mitigating risks and strengthening the resilience of the society. As demand for reinsurance solutions is growing and more sophisticated modelling allows for a better understanding of the risks, the underwriting terms for the reinsurance industry continue to improve allowing for more adequate risk premiums and enhanced economics.

Business Performance 2021

The profit before tax for 2021 amounts to EUR 26.8 million, giving rise to a shareholder return on Shareholders' equity of 10.0%. Combined ratio for the period was 96.1%, slightly decreased compared to 2020 by 0.8% percentage points.

The underwriting result reached EUR 20.2 million, heavily impacted by European natural catastrophic events, most notably Bernd and Volker, accounting for losses incurred of EUR 180 million for Bernd and EUR 150 million for Volker for VIG Re gross (net: EUR 7 million on both events and before reinstatement premiums due to the Company's prudent retrocession programme in place). Only minor Covid-19 related losses have been reported in underwriting year 2021.

The investment result accounted a return from investment of 1.2% (2020: 1.1%). It was affected by negative FX revaluation of assets held against liabilities in respective foreign currencies. Ordinary income developed according to the plan and additional extraordinary profit was realized by selling equity investment funds.

Administrative and other operating expenses amounted to EUR 13.8 million. Main expense categories are personal cost (60%), IT related costs (18%), outsourcing and consultancy (6%).

Table 4 - Income Statement (in '000 EUR)

	2021	2020
Premiums written	661 275	578 898
Property & Casualty	600 096	524 286
Life	32 867	26 257
Health	28 312	28 355
Combined ratio*	96.1%	96.9%
Result from investments	9 610	8 456
Profit before tax	26 846	22 560
Profit for the period	21 136	16 770

* Combined ratio is calculated for P&C and Health business segments

Reinsurance business assumed from insurance companies being member of VIG Group accounted for EUR 383 million, 11% above 2020 level, which is 58% of the total gross written premium. Out of this EUR 171 million referred to VIG Property and Casualty Treaty business. VIG Re closely cooperates with VIG holding and serves as a carrier that sets up Group wide reinsurance protection. Equally important is VIG Re's role as preferred reinsurer for VIG companies when meeting their individual reinsurance needs.

VIG Re's portfolio continues to diversify in terms of client base, lines of business and distribution channels. As in previous years, the Company succeeded to further grow the business assumed from clients outside of VIG Group.

As for Central and Eastern Europe, despite the ongoing market consolidation and centralisation of reinsurance buying of international insurance groups, the portfolio grew by 6% to EUR 54 million. Other non-life treaty business for underwriting year 2021 written from the Headquarter with clients outside of VIG Group includes Southern Europe (Italy, Spain, Portugal), accounting for EUR 36 million and East Asia (Japan, South Korea), accounting for EUR 23 million. The facultative property and casualty book grew by 7% to EUR 12 million.

Business assumed by VIG Re's branch in Germany, responsible for our non-life treaty business from clients outside of VIG Group in Germany, Austria, Switzerland and Nordics grew by EUR 17 million to EUR 82 million. By end of 2021 number of clients in the region grew to 76. Likewise, for the French branch office, which for the underwriting year 2021 served clients in France and Benelux, further inroads were made with prospect clients as well as existing ones, translating into a substantial growth of our portfolio and client base. The GWP grew by 59% to EUR 46 million. By end of 2021 VIG Re was servicing 58 clients in the region. The life and health portfolio grew from EUR 55 million to EUR 61 million. Since 2021 VIG Re is responsible, for the Group-wide life reinsurance protection, similar as for property and casualty.




Figure 2 - GWP per Segment in (EUR '000)

● P&C	600 096
● Health	28 312
● Life	32 687




Figure 3 - GWP P&C per Line of Business (in EUR '000)

● Property	422 946
● Motor Third Party Liability	91 318
● Motor Own Damage	34 735
● General Third Party Liability	21 006
● Marine	18 689
● Personal Accident	11 402




Figure 4 - GWP P&C per Country (in EUR '000)

● Austria	179 663
● Germany	61 468
● Czech Republic	52 815
● Italy	36 819
● Poland	34 389
● Turkey	28 676
● France	30 775
● Slovakia	15 929
● Japan	13 914
● Romania	15 233
● Other*	130 416

*Other represents the following countries: Albania, Armenia, Azerbaijan, Belgium, Bosnia, Bulgaria, Croatia, Estonia, Georgia, Greece, Hungary, Kazakhstan, Kosovo, Latvia, Liechtenstein, Lithuania, Luxembourg, Macedonia, Moldova, Montenegro, Netherlands, Portugal, Russia, Serbia, Slovenia, South Korea, Spain, Switzerland, Ukraine

The underwriting result for 2021 and 2020 is summarised in the following tables.

Table 5 - IFRS Results of 2021 (in EUR '000)

2021	P&C	Life	Health	Total
Premiums written - gross	576 794	32 867	51 615	661 275
Premiums written - reinsurers' share	-240 007	-8 494	-2 269	-250 770
Net earned premiums	330 981	24 016	49 582	404 579
Other income	0	2 662	10	2 672
Claims incurred	-240 311	-14 152	-46 925	-301 389
Operating expenses	-75 546	-7 238	-2 833	-85 617
Underwriting result	15 124	5 288	-166	20 246

Table 6 - IFRS Results of 2020 (in EUR '000)

2020	P&C	Life	Health	Total
Premiums written - gross	524 286	26 257	28 355	578 898
Premiums written - reinsurers' share	-204 479	-8 284	-1 828	-214 591
Net earned premiums	318 644	18 132	26 505	363 281
Other income	1	2 829	6	2 836
Claims incurred	-215 599	-10 629	-8 857	-235 085
Operating expenses	-98 603	-5 589	-11 480	-115 672
Underwriting result	4 442	4 744	6 174	15 360

The underwriting result per segments for 2021 and 2020 is presented in the tables below:

Table 7 - Underwriting Result per Segments 2021 (in EUR '000)

2021	Gross Earned Premium	Gross Claims & Expenses Incurred*	Gross Underwriting Result	Net Underwriting Result**
P&C CEE & VIG	374 075	-541 555	-167 480	4 025
Branch Germany	82 351	-150 754	-68 403	3 503
P&C SE	35 831	-39 229	-3 398	-5 547
Branch France	45 738	-51 343	-5 606	3 804
P&C Asia	23 413	-21 747	1 666	1 200
P&C Facultative	12 429	-8 226	4 203	1 516
Health	51 935	-51 040	895	6 493
Life	32 416	-24 840	7 576	5 252
Total	658 188	-888 735	-230 547	20 246

* Life underwriting result also includes income from the deposits to cedants in the "Gross Claims & Expenses Incurred".

**After all retrocession. Including admin costs.

Table 8 - Underwriting Result per Segments 2020 (in EUR '000)

2020	Gross Earned Premium	Gross Claims & Expenses Incurred*	Gross Underwriting Result	Net Underwriting Result**
P&C CEE & VIG	331 815	-278 393	53 423	7 773
Branch Germany	65 434	-66 121	-687	6 304
P&C SE	45 118	-47 470	-2 352	-2 750
Branch France	26 771	-29 183	-2 412	-2 108
P&C Asia	17 237	-17 077	160	596
P&C Facultative	11 615	-6 710	4 904	1 622
Health	52 616	-52 163	452	-302
Life	26 312	-21 161	5 150	4 227
Total	576 918	-518 278	58 640	15 360

* Life "Gross Claims & Expenses Incurred" includes income from the cedants deposits.

**After all retrocession. Including admin costs.

The underwriting result for the most important lines of business for 2021 and 2020 is presented in the following tables:

Table 9 - Underwriting Result per Solvency II Line of Business 2021 (in EUR '000)

2021	Gross Earned Premium	Gross Claims & Expenses Incurred	Gross Underwriting Result	Net Underwriting Result
Fire and other damage to property	236 473	-266 005	-29 532	-15 056
Non-proportional Property	200 500	-451 387	-250 887	7 499
Non-proportional Casualty	64 161	-41 529	22 632	6 728
Other motor	36 280	-36 754	-474	436
Motor vehicle liability	18 717	-18 592	125	159
Non-proportional health	26 441	-11 559	14 882	16 144
Life reinsurance	32 687	-24 970	7 717	5 393
Other	42 930	-37 940	4 990	-1 057
Total	658 188	-888 735	-230 547	20 246

Table 10 - Underwriting Result per Solvency II Line of Business 2020 (in EUR '000)

2020	Gross Earned Premium	Gross Claims & Expenses Incurred	Gross Underwriting Result	Net Underwriting Result
Fire and other damage to property	197 590	-213 995	-16 405	- 6 857
Non-proportional Property	170 995	-120 049	50 946	5 539
Non-proportional Casualty	58 022	-45 673	12 349	9 297
Other motor	37 953	-38 248	-295	-1 372
Motor vehicle liability	20 664	-22 019	-1 356	-1 242
Medical expense	26 688	-17 318	9 371	6 433
Life	26 431	-21 208	5 223	4 890
Other	38 575	-39 769	-1 194	- 1328
Total	576 918	-518 278	58 640	15 360

A.3 Investment Performance

A.3.1 Investment Performance in 2021

Bond markets had to contend with a rocky year of 2021, characterized by rising inflation, a bumpier economic recovery, and the start of tighter monetary policy. Although most enterprises more or less adapted to the repeating infection waves, the world trade suffered from the disrupted supply chains. With the support of very loose monetary and budgetary policies, the global economic recovery has been launched, but at the cost of a significant increase in inflationary pressures, the persistence of which gradually appears to be longer-term than originally expected. The optimism associated with the recovery and management of the pandemic situation in 2021 was reflected in the strengthening of the global stock market in local currencies by more than 20% (including dividends). The stretch for yield that began in 2020 continued, with lower-quality credit surging for much of the year.

The 4th quarter of 2021 was marked by volatile gas prices which contributed to higher inflation. The eurozone's annual inflation rate reached 4.9% in November, compared to -0.3% a year earlier. The European Central Bank stated that it would scale back bond purchases but ruled out interest rate rises in 2022.

VIG Re investments in 2021 were focused in the reinvestment area of maturing bonds and cash inflow from the reinsurance business. The share of government bonds decreased compared to 2020 due to these maturities. Free cash generated by underwriting activities was invested in corporate bonds and collective investment undertakings, while a significant part of it remained in cash due to the expected payments in 2022 for the nat cat events of summer 2021.

The composition of the investment portfolio in 2021 and 2020 is presented in the following table.

Table 11 - Investments (in EUR '000)

Investments	2021	2020
Property, plant & equipment held for own use	2 548	2 952
Investments	501 116	477 926
Holdings in related undertakings, including participations	8 663	6 648
Participations in fully consolidated insurance companies	0	0
Participations in fully consolidated non-insurance companies	8 663	6 648
Equities	1 173	1 337
Equities - listed	0	479
Equities - unlisted	1 173	858
Bonds	351 177	338 245
Government bonds	206 390	217 522
Corporate bonds	144 787	120 723
Collective Investments Undertakings	140 102	131 696
Deposits other than cash equivalents	0	0
Loans & mortgages	12 374	7 701
Deposits to cedants	105 828	116 137
Cash and cash equivalents	60 754	44 817
Total	682 621	649 533

The Company valued the participation in Wiener Re subsidiary at zero in 2021 (as in 2020) According to SII Regulation. VIG Re has no investments in securitisation.

The investment result per asset class for 2021 and 2020 is presented in the tables below:

Table 12 - Investment Result of Individual Assets Classes 2021 (in EUR '000)

Asset category	Dividends	Interest	Net gains and losses	Unrealised gains and losses
Government Bonds	0	3 017	1 250	-5 830
Corporate Bonds	0	2 209	-317	-5 168
Equity instruments	414	0	454	-446
Collective investments undertakings	798	0	2 263	-79
Cash and deposits	0	3 471	-1 475	-512
Mortgages and loans	0	178	17	-214
Other investments	0	0	0	0
Total	1 212	8 875	2 193	-12 248

Table 13 - Investment Result of Individual Assets Classes 2020 (in EUR '000)

Asset category	Dividends	Interest	Net gains and losses	Unrealised gains and losses
Government Bonds	0	3 825	1 580	-1 028
Corporate Bonds	0	2 103	-1 247	1 143
Equity instruments	417	0	0	336
Collective investments undertakings	805	0	737	355
Cash and deposits	0	3 675	-225	-131
Mortgages and loans	0	174	0	156
Other investments	0	0	0	0
Total	1 222	9 777	846	831

The revenues fully reflect the approved structure of the assets and their prudent risk profile. Reduction in interest from government bonds was mainly related to lower investment volume in this asset category and lower reinvestment yields at the same time. Net gains and losses are negatively influenced by currency devaluation in some currencies like TRY, UAH or HUF. On the other hand, this negative effect was compensated by realization of extraordinary profits, mainly from sale of the equity instruments and collective investment undertakings. Unrealized gains and losses were affected mainly by increasing yields and decreased prices of bond portfolio.

The expenses related to Investment activity in 2021 and 2020 are shown in the following table:

Table 14 - Expenses Related to Investment Activity (in EUR '000)

	2021	2020
Expenses of investment activity	1 937	2 449
Interest for deposits from retrocessionaires	447	851
Expenses of asset management and securities	56	198
Interest expenses of subordinated debt	1 434	1 400
Depreciation and costs of property	0	0
Other expenses	0	0

The expenses of investment activity decreased mainly due to the lower volume of deposits from retrocessionaires. Asset Management and securities expenses are mirroring lower investment activity during 2021 and the interest expense of subordinated debt includes accrued interest from newly issued subordinated certificates.

A.4 Performance of other Activities

The Company granted loans, which resulted in a receivable amount of EUR 12.4 million (2020: EUR 7.7 million), as shown in the Company's balance sheet.

A.5 Any Other Information

There is no other material information related to business performance.

SYSTEM
OF
GOVERNANCE



B.1 General Information on the System of Governance

The Company's system of governance is defined by valid and applicable law, a set of internal rules, procedures and reporting lines as governed by the documents of the Company (Articles of Association, Rules of Procedure of the corporate bodies) and other internal policies. The system of governance sets the overall responsibilities and tasks of the governing bodies of the Company, as well as all individuals. The system of governance encompasses also other integral elements, such as the risk management system (including the risk appetite framework, ORSA, etc.) and the interconnected internal control system and the key functions. All these elements contribute to a robust system of governance and efficient management of the Company. We discuss the individual elements in the following chapters.

B.1.1 Role and Responsibilities of the Board of Directors

The **Board of Directors** as the highest statutory body of the Company is responsible for the determination of objectives and business plans and fulfilling them, setting the organisational structure, setting the remuneration and ultimately takes ownership of all risks. In doing so, the Board of Directors follows the tasks, as assigned to it by the valid and applicable (inter alia Act no. 90/2012 on Business Companies and Cooperatives (on Business Corporations), as amended (hereinafter the "**Act on Business Corporations**") and Insurance Act) and internal documents (decisions of the General Meeting, the Company's Articles of Association, Rules of Procedure of the Board of Directors, etc. Following the resignation of a board member in December 2020, a new Board of Directors member has been appointed in May 2021.

Four committees are established in order to support the Board of Directors, as follows:

The **Committee for Technical Reserves** is a collective body, which particularly advises the Board of Directors in its decision making in respect of appropriate technical reserving to ensure long-term financial stability of the Company when meeting its objectives. The Committee is chaired by the Head of Actuarial Services and Retrocession department and is held at least on a quarterly basis.

The **Risk and Compliance Committee** is a collective body, which particularly advises the Board of Directors in its decision-making process in respect of risk and compliance situation of the Company, e.g. risk profile, its adequate measurement and steering within risk strategy of the Company. The Committee is chaired by the Chief Risk Officer and is held at least on quarterly basis.

The **Underwriting Committee** is a collective body, which particularly ensures that reinsurance business assumed ("underwritten") by the Company is aligned with the Company's Underwriting Guidelines, taking into account the Company's business strategy, risk strategy, its values and long-term strategy as well as the nature, scale and complexity of the risks inherent to the business. The Committee is chaired by the Chief Underwriting Officer and is held at least on quarterly basis.

The Company has also set up a **Remuneration Committee** as a collective body which deals with the matters concerning the remuneration of employees performing key functions of the Company. The members are the Head of HR department of Kooperativa pojišťovna, a.s., Vienna Insurance Group and the HR Business Partner of the Company.

B.1.2 Role and Responsibilities of the Supervisory Board

The Supervisory Board oversees the operations of the Company and the actions of the Board of Directors. The Supervisory Board provides assurance on the reported results to the shareholders, the accuracy of the administrative and accounting processes, process efficiency, etc.

The Supervisory Board meets regularly four times a year. The regular agenda includes the Company's strategy, business plan, report from the Audit Committee, management report, report on business activities, report on Wiener Re (subsidiary company of VIG Re), but also other relevant key topics.

The Supervisory Board was also informed about the development of the solvency position of VIG Re and subsequently measures were taken to manage the solvency ratio within the defined comfort zone.

The Supervisory Board was strengthened by two new members in 2021 and five members were re-elected. The list of members is to be found in the Annual Report 2021.

The Supervisory Board sets up its committees to support its oversight activities. The committees directly and significantly represent the interests of the Company's shareholders.

The following committees are established at VIG Re:

- Committee for the Matters of the Board of Directors,
- Committee for Urgent Matters,
- Strategic Committee.

The **Committee for the Matters of the Board of Directors** is a collective body whose members are appointed by the Supervisory Board from amongst its members. The Committee for the Matters of the Board of Directors deals with matters concerning the Board of Directors if these matters fall within the competence of the Supervisory Board.

The **Committee for Urgent Matters** is a collective body whose members are appointed by the Supervisory Board from amongst its members. The Committee for Urgent Matters deals with issues which, due to their special urgency, cannot be postponed until the next meeting of the Supervisory Board. The Committee for Urgent Matters is particularly authorized to grant consent to acts and measures for which the consent of the Supervisory Board is otherwise required pursuant to the Articles of Association or the Rules of Procedure of the Board of Directors. The Committee for the Urgent Matters did not convene any meeting during 2021.

The **Strategic Committee** of the Supervisory Board was dissolved by the decision of the Supervisory Board at its meeting held on 22 April 2021.

In addition to the aforementioned committees, the Company has established the Audit Committee as a corporate body of the Company.

The **Audit Committee** monitors the process of preparation of financial statements, assesses the efficiency and effectiveness of the internal controls and internal audit, oversees the external audit of financial statements and assesses the suitability and independence of the external auditor. It also recommends the statutory auditor to the Supervisory Board. There was no change to the organizational structure of the Audit Committee over the course of 2021 and the list of its members is to be found in the Annual Report 2021.

B.1.3 General Information on Second and Third Line of Defence Functions

The authority, resources and operational independence of the key functions is as follows:

Actuarial Function – Following the resignation of the actuarial function holder, the actuarial function was assigned to the Chief Risk Officer at the end of 2021. The function is a unit independent from the Actuarial Services and Retrocession department. Information on the authority, resources and independence of the actuarial function is provided in chapter B.7. Actuarial Function.

Risk Management Function – The function is assigned to the Chief Risk Officer who is responsible for the implementation of an adequate risk management system and maintains independence by carrying out an oversight role in the major processes, allowing for robust challenge of decisions and processes across the business. Asset risk management is outsourced to Asset Risk Management department of Kooperativa pojišťovna, a.s., Vienna Insurance Group (see chapter B.8 Outsourcing) which is in close cooperation with the Risk Management Function. Details of responsibilities and processes are provided in chapter B.3.

Compliance Function – The function is assigned to the Chief Compliance Officer. The Compliance Function Holder at VIG Re is the representative towards the state authority and holds the ultimate responsibility for the Compliance Function. The task of the Compliance Function is to ensure that all the key risks are properly managed and that the Company is conducting its business in full compliance with applicable laws. More information on the implementation, authority and independence is provided in chapter B.5.

Internal Audit Function – the Internal Audit Function Holder is the member of the Board of Directors on an interim basis until the internal auditor is eligible for this function. The Internal Audit Function maintains independence as the officers that conduct the audit work are from an external organization (please refer to chapter B.8 Outsourcing). More information on the implementation, authority and independence is provided in chapter B.6.

Corporate Underwriting is a department whose responsibilities are also related to the second line of defence. The department monitors the underwriting risk profile of the Company and the portfolio development by line of business and market segments ensuring that the underwritten business is in compliance with the Risk Strategy and Underwriting Guidelines.

For further details on organisational structure, please refer to Annex 1.

B.1.4 Principles of Remuneration of Members of the Corporate Bodies and Key Function Holders

The rules for remuneration are governed by the Remuneration Policy, which lays down the aspects of remuneration in accordance with the requirements set out by the Solvency II regime as well as the VIG Group Remuneration Policy.

The purpose is to ensure a general framework for:

- establishing, implementing and maintaining remuneration practices in line with the Company's business and risk management strategy, its risk profile, objectives, risk management practices as well as long-term interests and performance,
- measures aimed at avoiding conflicts of interest and excessive risk-taking at the expense of the Company or its stakeholders.

Remuneration Components

Remuneration is the financial compensation paid to an individual by a company in exchange for his or her work. Remuneration consists of a fixed and a variable component.

Fixed remuneration is a predefined amount of money a person receives as a fixed payment in regular instalments.

Variable remuneration is the amount that is related to performance and it is not a claimable component of the overall salary if performance requirements are not met. Variable remuneration must not be based solely on financial criteria.

In general, the fixed component for members of the Corporate Bodies and Key Function Holders creates 65-75% of the total annual remuneration and the variable part accounts for 25-35%.

Remuneration Schemes for Specific Types of Personnel

A specific remuneration policy applies to the members of the Board of Directors, other employees with material impact on VIG Re's risk profile and holders of the key functions.

In general, the remuneration for those types of personnel contains a variable component which shall be based on a combination of:

- Company's performance and basic KPIs
- Group financial year performance (for Board Members only)
- Individual's performance, related to the fulfilment and the quality of specified tasks taking into account the responsible handling of risks and compliance with laws, internal rules and risk management practices,
- Underwriting performance of a specific profit centre (for employees with material impact on the risk profile)

Goals are set up with a care to ensure that there is no conflict of interest to fulfil the goal. Subject to the principle of proportionality, a substantial part of the variable remuneration is deferred. The deferral period is set at three years. The deferred part accounts for 30-40% of variable remuneration.

The remuneration for the key function holder does not contain targets related to the Company or Group financial or Solvency performance-related components.

The remuneration for the function of a member of the Supervisory Board and Audit Committee does not contain any performance-related components.

Supplementary Pension Schemes

The Company has no supplementary pension or early retirement schemes in place for the members of the Board of Directors, Supervisory Board, Audit Committee and other key function holders.

B.1.5 Regular Review of the System of Governance

Given that VIG Re's business, and organisation are steadily growing, the system of governance is continually adjusted according to the developing risk landscape of the Company's business model. The adequacy of system of governance is a regular point on the agenda of the Board of Directors meetings.

In 2021 the Company continued to strengthen its underwriting and risk management capabilities. Changes of the Company to its organisational structure, as can be seen in Annex I, have been implemented in order to foster the growth of the Company with emphasis on the enlarging territorial scope. The main revisions referred to the responsibilities of the market units, and clear definitions of key functions versus business functions.

Facultative business is one of the dedicated growth areas within the VIG Re Strategy 25 and expected significant contributor in the future, hence a new head of department was assigned and additional resources have been allocated to it.

A new head of Business Administration has been assigned and joined the Company at the beginning of 2022.

Moreover, the proper supervision of the Company's management has been strengthened by appointing two additional members of the Supervisory Board in 2021.

There were no other material transactions during the reporting period with shareholders, with persons who exercise a significant influence on the undertaking, and with members of the Board of Directors, the Supervisory Board and the Audit Committee.

B.2 Fit and Proper Requirements

The fit and proper requirements apply to Supervisory Board, all persons who effectively run the Company, persons performing key functions and persons with material impact on the Company's risk profile. This area is governed by the Fit and Proper Guideline while specific requirements for key function holders are defined in the policies defining these function roles and responsibility.

- a) Supervisory Board
- b) Persons who Effectively run the Company:
 - Members of the Board of Directors.
- c) Persons Performing Key Functions:
 - Internal Audit Function,
 - Compliance Function,
 - Risk Management Function,
 - Actuarial Function,
- d) Specific Persons Ensuring the Company's Activities

Before appointing an individual to the aforementioned positions, the Company assesses whether the criteria of fitness and propriety, as listed below, are fulfilled by the individual, based on the information provided by them. Each individual has a duty to ensure that they meet the criteria for the duration of their appointment and duly report if they no longer comply with them. The Company reviews the Fit and Proper Guideline regularly, including the list on persons that are subject to it.

B.2.1 Fit Requirements

When assessing whether a person is fit, the Company ensures that this person has the necessary personal and professional qualifications and takes into account the respective duties to be allocated to individual person to ensure appropriate diversity of qualifications, knowledge and relevant experience so that the Company is managed and overseen in a professional manner.

Additionally, the Company has to ensure that persons who effectively run the Company collectively possess appropriate qualification, experience and knowledge about at least:

- Insurance, reinsurance and Financial Markets,
- Business Strategy,
- Corporate Governance,
- Financial and Actuarial Analysis,
- Regulatory Framework and Requirements,
- Risk management system.

For key function holders, specific criteria for their education and experience in respective fields are laid down in internal guidelines for each key function.

B.2.2 Proper Requirements

When assessing whether a person is proper, the Company takes into consideration the following elements:

- an actual or potential conflict of interest, other financial interests or close relationship to others at the Company,
- integrity,
- credibility - current or past involvement in the bankruptcy proceedings,
- severe current or past disciplinary or administrative penalty proceedings in connection with a position in a financial institution,
- previous rejection by a supervisory authority for a key function in a financial institution,
- current or past proceedings on revocation or limitation of a professional practice license in the financial industry.

B.3 Risk Management System Including the Own Risk and Solvency Assessment

VIG Re's risk management system is based on principles ensuring effective performance of all activities in the Company and is organised in a way that provides:

- Integrity and ethical values,
- Conflict of interest prevention,
- Allocation of responsibilities,
- Motivation alignment with Company's targets, and
- Four-eye principle.

Own Risk and Solvency Assessment, as one of the key elements of risk management system, is further discussed in chapter B.3.4.

B.3.1 Risk Management Roles and Responsibilities

Risk management system forms an integral and key element of the system of governance and has been established on the basis of the three lines of defence concept. The core principle of this concept embeds a transparent segregation of responsibilities into three different lines of defence, that are intended to avoid conflicts of interests, and the set-up of a system of prevention and effective controls.

First Line of Defence

The first line of defence comprises all organisational units of the Company that participate in activities exposing the Company to risks. These units and their directors take the ownership of the risks including their identification, analysis, risk control application and day-to-day management.

Second Line of Defence

The second line of defence represents activities performed to set up the risk management system and oversee the risk-taking activities whereas an integral part is the continuous supervision of day-to-day risk management and the control mechanisms and monitoring activities of departments included in the first line of defence.

At VIG Re, the second line of defence is conducted by the Risk Management Function, Actuarial Function, Compliance Function and Corporate Underwriting. Their roles and responsibilities are defined in specific internal standards and further discussed in the following chapters.

Third Line of Defence

The third line of defence consists of functions whose task is to provide independent assurance to the shareholders, the Supervisory Board and the Board of Directors regarding the setting, implementation and performance of all processes carried out by the first and the second line of defence. At VIG Re, the third line of defence is represented by the Internal Audit Function. Its roles and responsibilities are defined in a separate internal standard.

In relation to the organisational separation of individual departments into the respective lines of business, the principle of proportionality is applied given the size of VIG Re. However, where a possible conflict of interest cannot be avoided by effective organisational separation, the aim is to elevate such conflict to the highest possible organisational level, i.e. to the Board of Directors.

As a natural consequence of the separation of lines of defence, the Company has established several committees as advisory bodies to the Board of Directors. These committees serve as means of discussion of common topics between the lines of defence. The established committees are described in chapter B.1. The hierarchy of statutory bodies and organisational units related to risk management system at VIG Re are illustrated in the following chart.

Figure 5 - Statutory Bodies and Organisational Units in the Company



The functions' independence is ensured by the fact that the persons responsible for key functions have direct access to the Board of Directors. This direct access also allows the Board of Directors to have insight to the areas covered by the key functions and have access to the necessary information in order to more strictly exercise its duties. The cooperation between the functions and first line of defence is accomplished through the committees with the participation of representatives from both lines of defence.

The organisational structure, which defines the bodies of the Company, is governed by the organizational regulations and is regularly updated.

Board of Directors

The overall responsibility of risk management system is in the Board of Directors. The Board of Directors is accountable for determining and approving the risk strategy, including the risk appetite framework and the derived limits for individual risks, internal policies and organisational chart. These define the tasks and responsibilities of organisational units and individuals in the risk management system and internal control system. The Board of Directors regularly monitors and discusses the risk profile of the Company, including the risk exposures and potential breaches to the limits.

Risk and Compliance Committee

In order to further strengthen the risk management culture within the Company and to integrate the Risk Owners in the risk management process, the Company established the Risk and Compliance Committee. The Committee provides information regarding risk related topics and also supports and advises the Board of Directors in its decision-making process. The responsibilities of the Committee are discussed in the rules of procedures approved by the Board of Directors.

Risk Management Function

Risk Management function oversees the processes of aggregation and reporting of SCR results, ensures data quality controls are in place in these areas and implements the risk management framework based on the Company's risk strategy. Moreover, risk management conducts the internal control system assessment on an annual basis by performing interviews with the respective risk owners in order to identify new operational risks, assess the existing risks and their control effectiveness. Risk inventory process and steering of the ORSA process are also in the responsibilities of Risk Management.

Risk Management prepares regular internal risk reports, reports on other risk-related topics to the Board of Directors and is also engaged in the preparation of reports to the supervisory authority (QRTs, RSR and SFCR). Besides the aforementioned activities, the function fulfils additionally regular tasks to ensure an overall well-functioning of Risk Management System at VIG Re. This includes but is not limited to:

- screening of regulatory developments in the area of risk management,
- raising awareness at VIG Re about risk alignment of risk management activities throughout VIG Re,
- regular interaction with key stakeholders as risk owners and Board Members,
- proactively monitoring and evaluating the overall risk situation at VIG Re.

The Chief Risk Officer, who simultaneously holds the risk management function, is responsible for the implementation, maintenance and development of the risk management system and reports directly to the Board of Directors.

B.3.2 Risk Management Process Implementation

Risk Strategy

Given the business activities as a reinsurance company, VIG Re is exposed to a variety of risks. The Company identifies underwriting risk in non-life, health and life reinsurance business, market risk stemming mainly from investments, credit risk resulting from business relations and other general risks such as operational, reputational and strategic risk.

The Risk Strategy provides an overview of the risks related to the strategic initiatives and financial goals of VIG Re and the respective strategies and principles to manage and mitigate those risks. The Company's risk appetite is defined as the aggregate level and type of risk that is willing and has the capacity to take in order to achieve its objectives. The risk appetite depends on the balance achieved between the solvency position, shareholders' requirements on profitability, risk expertise and possible risk mitigation. For VIG Re, risk strategy covers risk appetite for these parameters by setting quantitative statements on:

- Profitability, Combined Ratio and Solvency Comfort zone as financial goals.
- Solvency ratio, Capital Requirement and Own Funds as risk indicator.

The risk strategy qualitatively determines its risk appetite based on the expertise, experience and capacity of the Company for different types of risks as follows:

- Accepted risks,
- Conditionally accepted risks,
- Not accepted risks.

Risk mitigation principles and technics are specified for each risk category individually.

The Company is committed not to endanger the risk strategy while improving the financial KPIs. Hence, a set of limits are established to allow the management of the Company to monitor the performance on an on-going basis, ensuring that the goals of risk strategy are met.

In line with the risk strategy, VIG Re has implemented a risk management process framework, which covers the following steps:

Risk Identification

Identification is the starting point of the risk management process and sets the foundation of the subsequent steps. The aim of risk identification is to expose, detect and document all possible sources of risks, which could affect the achievement of VIG Re's objectives, and define the control mechanisms to be used to manage the risks. All identified risks are classified into defined risk categories. The outcome of this process is the risk inventory report, which is updated regularly, at least on an annual basis. Risk identification is performed in a close cooperation with the first line of defence, i.e. the Heads of the business departments.

Risk Measurement and Analysis

Following the risk identification, an essential prerequisite for adequate risk handling and decision-making process is the measurement and analysis of all risks identified including their materiality evaluation. On this basis, different assessment methods are used for each risk type in line with the proportionality principle.

An important method for risk measurement is the Solvency Capital Requirement calculation for each risk by means of the standard formula approach and the partial internal model. Additionally, the Company uses VaR methods to measure its market risks. Operational risks are defined and assessed through the Internal Control System and, are evaluated and monitored using frequency and severity approach. For risks that are not easily feasible to quantify, such as reputational and strategic risks, VIG Re uses experts' evaluations. The risk measurement is performed and aggregated by the risk management function in close cooperation with the first line of defence.

Risk Management Decision and Execution

Once a risk has been measured, either quantitatively or qualitatively, and materiality being stated, measures and mechanisms are assessed for the acceptance or change of the risk situation. The main outcomes of a decision as part of the risk management are as follows: risk avoidance, risk acceptance or conditionally risk acceptance including risk mitigation techniques. This step is supported by the ORSA process, the Internal Control System and the decisions and recommendations of committees which are taken into consideration for the conduction and review of the risk strategy by the Board of Directors.

Risk Monitoring and Risk Reporting

Risk monitoring forms an essential part of the risk management process and is divided into two different areas. Firstly, risk monitoring refers to the process of ensuring that the risk profile of VIG Re remains in line with the risk appetite and the risk strategy at all times. This is ensured by the risk bearing capacity and its limit system in terms of capital requirements, but also by other internal processes as the referral process, risk accumulation monitoring and limits monitoring. Risk monitoring refers also to the follow-up process during and after the implementation of decisions for risk treatment as described in the previous step. In that case, risk monitoring aims to control the effective and timely implementation of decided action plans.

Internal risk reports are regularly prepared by the risk management function and are subsequently submitted and discussed in the Risk and Compliance Committee and Board of Directors for the aforementioned areas, including the SCR and VaR calculations as well as reports on other risk-related topics such as sensitivity analyses and stress tests.

Risk management monitors risk categories development and its alignment with Company's goals by making use of back testing the projected risk profile with actual outcomes and by comparing the development of the Company's own funds with risk appetite of the Company. This process is part of the risk bearing capacity process of the Company, which is assessed annually.

B.3.3 Governance of the Partial Internal Model

VIG Re uses a partial internal model (PIM) for the non-life underwriting risk and the NSLT health underwriting risk.

The Board of Directors of VIG Re is responsible for the establishment of the overall framework and the areas of specific responsibilities are outlined as follows:

Table 15 – Responsibilities of PIM Processes

Process	Responsibility
SCR aggregation	Risk Management Function
Validation	Risk Management Function
Data Quality	Data Quality Manager
Technical Provisions	Actuarial Function
External Models	Head of Actuarial Services and Retrocession
Model Use	Head of Actuarial Services and Retrocession
Model Change	Risk Management Function
Integration	Risk Management Function
Documentation	Risk Management Function

The use of the model in various areas supports a sustainable development of the Company and risk management; hence, the model results are of a high importance to the management body of VIG Re. The partial internal model is used in the areas of business planning, pricing of the assumed reinsurance portfolio, accumulation control of business exposed to natural catastrophes and retrocession optimization of VIG Re.

In order to ensure appropriateness of the results, the PIM is subject to certain requirements which are assessed in the validation process. The main purpose of the validation is to ensure that the partial internal model provides an adequate and robust assessment of risks undertaken by the Company. The validation is performed while ensuring adequate independence between the model validation and model operation parties. The results of the validation are submitted to and approved by the Board of Directors.

The model processes, as set out in Table 15, are governed by clearly defined rules and procedures which are outlined in the Company's internal standards.

B.3.4 ORSA Process

The Own Risk and Solvency Assessment ("ORSA") process is a continuous operating process that provides assurance that the risk situation is considered in the decision-making process of the Company and serves as an important tool for sustainable business management. The process is coordinated by the risk management function of the Company. The process is organized in a manner which ensures the delivery of a proper assessment and a calculation within the agreed timelines as set by VIG and other regulatory bodies. This assessment is an integral part of the business strategy and is taken into account in strategic decisions of the Company on a continuous basis. The assessment comprises the following elements:

- Analysis of the Company's risk profile and overall Solvency needs given the approved risk tolerance limits and the Company's strategy,
- Analysis of the Company's compliance with the capital requirements and the requirements regarding technical provisions as laid down in the directive Solvency II, on a continuous basis,
- Deviations of Company's risk profile from the assumptions underlying the Solvency Capital Requirement calculated by the standard formula and the assessment of PIM appropriateness of assumptions,
- Forward-looking assessment in accordance with the Company's business plan, including stress test analysis.

The BoD of the Company is in general responsible for the adequate design, implementation and performance of the ORSA within the Company, the approval and the application of the ORSA guideline. Various departments are involved in the ORSA process to the extent of providing data, calculations and other information required for the risk assessment. Risk management shall coordinate the whole process and carry out the solvency needs projections and assessment of the risk profile. The process is concluded in the ORSA report summarizing the main results of each step. Release of the report is subject to a review and approval of the Board of Directors.

In order to adequately assess the risk profile and overall solvency needs of the Company, all risks the Company is exposed to are identified and categorized. On this basis, the Company assesses the risk with adequate quantitative and/or qualitative methods according to the nature and the materiality of the risk.

As a result of the business planning of the Company, the overall solvency needs, the regulatory capital needs and the available capital are assessed over the business planning horizon of the Company. The projection considers the latest forecasts in conjunction with the solvency estimations that were performed before. Based on suitable stress and scenario analyses the Company assesses the effects of possible deviations of the business planning or external factors on the solvency position of the Company. The projections and scenario analysis of the Company are taken into account in the final business planning.

VIG Re performs the regular ORSA on an annual basis. The regular ORSA frequency setting is based on the VIG Re long-term strategies, its risk profile, the volatility of the solvency needs relative to the capital position, the planning and business development. In case the results of the ORSA or other factors indicate the inadequacy of the defined frequency for the regular ORSA, the process is adjusted according the needs. In case of a significant change in the risk profile or a significant change is expected based on the experience of previously performed stress and scenario analysis, the Company performs an ad-hoc ORSA after the significant change is detected. The Company performs business planning for three-year horizon which is used as a basis for the projection of the expected solvency position.

Process Overview

The four main process steps of the ORSA assessment are illustrated below:

Figure 6 - ORSA Process



B.4 Internal Control System

The ICS is a continuously operating process that provides an appropriate control environment with effective controls. This is relevant for compliance with national and European law, and also serves as important tool for sustainable business management. The control environment must be well-based on the organisational and operational structure, with clear communication and monitoring procedures. The ICS provides reasonable assurance of:

- effectiveness and efficiency of operations,
- reliability of financial and non-financial information,
- adequate controls for operational risks,
- a prudent approach to business,
- compliance with laws and regulatory requirements, and
- compliance with the Company's strategies, policies, processes and reporting procedures.

VIG Re stresses the importance of an efficient internal control system for managing the operational risk in the day-to-day activities of all employees. Therefore, the ICS is developed in close connection to the risks identified in the Risk Inventory – the control mechanisms are proportionate to the nature, scale and complexity of the risks. Every department and their directors are responsible for development of the internal controls in their area of responsibility, carrying out the defined controls and reporting of findings. The development of ICS is coordinated by the Chief Risk Officer who also oversees the execution of internal controls and their results and may recommend changes to the system or its particular parts. Compliance Function is responsible for evaluating compliance risks and controls, and Internal Audit Function is responsible for an independent audit/review in accordance with the internal audit plan.

A distinctive control culture forms the basis for an effective ICS within VIG Re. The Company is responsible to ensure an effective ICS along with the existing control culture and environment being satisfactorily maintained and developed.

Standard 1 - The Company establishes and fosters a control culture that demonstrates the importance of controls throughout the Company at all levels of personnel.

Standard 2 - The Company establishes and maintains an organizational and operational structure that is adequate in the scale and complexity to the areas of business in which the Company operates.

Standard 3 - Roles and responsibilities are defined in a clear and appropriate way. In this respect, it is assured that necessary controls are implemented to prevent a conflict of interests.

Standard 4 - The Company identifies and assesses risks resulting from its activities and processes that could adversely affect the Company's goals. Moreover, the Company establishes and maintains effective controls aligned to these risks to ensure the achievement of these goals.

Standard 5 - Controls are applied at different levels of the organizational and operational structures, at different time periods and with different levels of detail as needed. The control activities are proportionate to the underlying risk.

Standard 6 - Effective channels of communication and information systems are established to ensure that the full staff clearly understands and adheres to policies and procedures affecting their duties and responsibilities, and that relevant information reaches the appropriate personnel.

The ICS assessment process is performed annually. The centrepiece of the ICS assessment is the documentation and the assessment of risks and controls in the risk and control matrix (RCM). Its objective is to identify, document and assess all operational and compliance risks together with the existing controls aimed at the mitigation of these risks. This allows to identify possible weaknesses and control deficiencies within the ICS so that appropriate measures and actions for remediation may be taken in a timely manner.

The overall efficiency of controls remained at 93.9. % in 2021. Based on these results the ICS is according to VIG Group standards considered as mostly effective.

The Internal Control Report is produced at least annually, and it summarizes the effectiveness of the ICS. Part of this report is designated to the assessment of the Compliance Function in accordance with Article 46(2) of Directive 2009/138/EC.

Even though the economic and social impacts of the outbreak of COVID-19 pandemic were less severe compared to 2020, VIG Re continued to focus on the protection of the health of our employees in order to ensure the processes associated with providing reinsurance services and maintain a standard level of service for our business partners. For this purpose, the continuity of the Company is deemed stable and secured. Similarly to 2020, the crisis management team met on a regular basis, assessed the development of the situation and approved measures as appropriate in line with the Business Continuity Guideline.

B.5 Compliance Function

The Compliance Function, as a second line of defence function, is an independent function responsible for identification, assessment, oversight and reporting the compliance risks arising from operational business units. These departments, as the first line of defence, bear the responsibility for managing their own compliance risks and avoidance of non-compliance in the areas they are responsible for. The Compliance Function monitors the activities of the first line of defence units in the area of compliance, coordinates the compliance risk management throughout the Company and carries out independent compliance checks and reports the findings to the Risk and Compliance Committee and Board of Directors.

The Compliance Function has the following duties and responsibilities:

- Providing Advice – The Compliance Function advises the Board of Directors and the Supervisory Board in compliance relevant areas.
- Compliance Risk Management
 - Compliance Risk Identification and Assessment - The Compliance Function identifies and assesses compliance risks, monitors and tests business activities to evaluate adequacy and effectiveness of control processes from the compliance standpoint (following a risk-based approach).
 - Compliance Risk Mitigation - The Compliance Function takes mitigating actions to reduce the source or the impact of compliance risks through the implementation of extra control measures (in particular, drawing up internal guidelines and controls, support in setting up specific working procedures and specific trainings etc.).

- Compliance Risk Monitoring - The Compliance Function monitors compliance risks and the effectiveness of the mitigating actions implemented. This monitoring includes carrying out compliance audits where the adequacy of the measures taken by the Company to prevent non-compliance are evaluated.
- Reporting Current and potential compliance risks identified as well as mitigating actions connected herewith shall be included into regular or ad hoc Compliance Report of a Compliance Function accordingly.
- Handling of Compliance Incidents
 - Cases where laws or regulations are violated by Company bodies or employees, are to be reported to and investigated by the Compliance Function or to other pre-defined body (Risk and Compliance Committee, Board of Directors). If the investigation reveals insufficiencies of implemented processes in the compliance field, the Compliance Function shall implement adequate measures to prevent future non-compliance.

During the year 2021, based on the compliance plan approved by Board of Directors, the Compliance function concentrated on the area of data protection, anti – money laundering and international economic sanctions and embargoes.

B.6 Internal Audit Function

The Internal Audit Function is part of the third line of defence in the Company.

The Internal Audit Function is outsourced to VIENNA INSURANCE GROUP AG, Wiener Versicherung Gruppe. The persons who carry out the audits and report the findings are independent from those who work in the areas under review. In addition, the Company is subject to group internal audits carried out in accordance with the group internal audit plan.

Within his responsibilities, the Head of Internal Audit meets the Chairman of the Supervisory Board and the Chairman of the Audit Committee on at least annual basis to discuss performed assessments, findings and recommendations made. The Internal Audit Plan is acknowledged by the Audit Committee and consequently also by the Supervisory Board.

The internal audit is a joint responsibility of all members of the Board of Directors. The Internal Audit Function Holder is currently a member of the Board of Directors.

The internal Audit Function is an activity that is independent of the day to day work process. It performs its duties autonomously, objectively, and impartially, thereby ensuring its independence.

The Internal Audit Function systematically and objectively audits and assesses:

- Measures to achieve the goals of the Company,
- Quality and economic efficiency of the duties performed,
- Risk situations,
- Effectiveness and economic efficiency of internal control system.

The Internal Audit department has an unrestricted active and passive right to inspection. Their access to information extends to all data and storage media.

During 2021, two internal audits were performed in the area of Economic Services and Purchasing and Services. None of the findings had a material risk associated. Most of the recommendations were already fulfilled as of end of the year 2021.

B.7 Actuarial Function

The Actuarial Function forms the second line of defence of the Company's risk management system that is an independent role responsible for key tasks related to technical provisions, maintaining an important role in underwriting, retrocession and risk management framework. The Actuarial Function Holder reports directly to the Board of Directors.

The tasks of Actuarial Function are split into 3 areas as stated below. The terminology "technical provisions" in this report refers to the technical provisions calculated in line with the Solvency II principles. This covers the areas of life, health and non-life reinsurance.

The activities performed per area, are as follows:

- **Technical Provisions**
 - coordinate the calculation of technical provisions,
 - ensure the appropriateness of the methodologies and underlying models used as well as the assumptions made in the calculation of technical provisions,
 - assess the sufficiency and quality of the data used in the calculation of technical provisions,
 - compare best estimates against experience,
 - oversee the calculation of technical provisions in the cases set out in Article 82 of the Directive 2009/138/EC (Data quality and application of approximations, including case-by-case approaches, for technical provisions).
- **Informing and Providing Opinion**
 - inform the Board of Directors of VIG Re about the reliability and adequacy of the calculation of technical provisions,
 - express an opinion on the overall underwriting policy,
 - express an opinion on the adequacy of retrocession arrangements.
- **Risk Management**
 - contribute to the effective implementation of the risk-management system referred to in Article 44 of the Directive 2009/138/EC, in particular with respect to the risk modelling underlying the calculation of the capital requirements set out in Chapter VI, Sections 4 and 5, and to the assessment referred to in Article 45 of the Directive 2009/138/EC;
 - contribute to the design of Solvency II (partial) internal model.

It is worth noting that the Actuarial Function Holder is an independent function from the Actuarial Services and Retrocession department. The Actuarial Function Holder is a voting member of the Technical Reserving Committee and summarises its opinions in the Actuarial Function report on annual basis.

B.8 Outsourcing

When using outsourcing, in particular as concerns the outsourcing of decisive or significant operational functions or activities (hereinafter only as "Critical outsourcing"), there shall be no:

- material impairing of the quality of the Company's system of governance,
- excessive increase of operating risk,
- impairing of the Czech National Bank's ability to monitor the compliance of the Company's obligations,
- undermining continuous and satisfactory service to the Company's clients.

In order to mitigate risks in connection with outsourcing, a service provider to which a function or activity should be outsourced, is being selected with due diligence. Outsourcing critical or important function or activities (hereinafter also as "Critical outsourcing") is being treated with special utmost care.

The Board of Directors decides about the outsourcing of the critical or important function or activity based on proposal of the person responsible for overseeing of the complete process of the Critical outsourcing (hereinafter only as "Responsible person"). The proposal must always be commented by relevant persons and departments (e.g. Legal Department, Compliance Officer). Any decision about the outsourcing of any critical or important function or activity must be reported to the Czech National Bank in advance.

The contract on outsourcing of decisive or significant operational activities must contain several provisions to assure the compliance with Solvency II and implementing legislation. Czech National Bank shall be informed in case of any serious development.

The Responsible Person is responsible for the ongoing quality control of the provided activity, overseeing fulfilment of the provider's obligations and submitting an evaluation report to the Board of Directors for the approval on the annual basis. In addition, there are regular feedbacks and discussions with the provider on the requirements and needs and on their fulfilment.

The outsourcing providers are located either in the Czech Republic, Austria, Germany, or in France.

The Critical Outsourcing is due to the proportionality principle being contracted exclusively within the group on long-term basis. Criteria used for assessing whether any activity will be outsourced are economies of scale and group efficiencies, large costs related to setting up the internal capacity, transfer of knowledge, etc. Areas, where the economies of scale are not able to materialize or the complexity of reinsurance business is too high to benefit from synergies within the Group, were insourced during the past several years.

VIG Re outsources the following critical activities to entities belonging to the VIG Group:

- Internal Audit,
- Economic Services,
- Asset Management,
- IT & IT Security Function.

B.9 Any Other Information

The Company has not identified any other information to be disclosed in this chapter. There were no other significant transactions with the shareholders, Board of Directors or members of other statutory bodies than already described above.

R I S K
P R O F I L E



Based on its activities as a reinsurance Company, VIG Re is exposed to a variety of risks which are intentionally accepted, monitored and mitigated according to defined principles of the risk strategy. These risks encompass underwriting risk in non-life, health and life reinsurance business, market risk stemming mainly from investments, credit risk resulting from business relations and other general risks such as operational and reputational risk.

Details in respect of the risk profile of the Company are further discussed in the risk inventory report issued on an annual basis. Particular risks are assessed by making use of both quantitative methods as described in chapter E.2 Solvency Capital Requirement and Minimum Capital Requirement, and qualitative methods (Severity and Probability Assessment), the later mainly for operational risk assessment. The Company ensures the capitalization within predefined risk tolerance limits through the risk bearing capacity analysis performed on quarterly basis.

Given reinsurance being the core activity of the Company, underwriting risk constitutes the most important risk class for VIG Re, more specifically non-life underwriting risk being the most significant risk contributor. The composition of risk categories in capital requirement after diversification is depicted in in the chart below.

Figure 7 - Composition of the SCR 2021



The Total Solvency capital requirement increased to EUR 155.8 million as of 31 December 2021 (2020: EUR 125.1 million). The year over year SCR growth is attributed to several risk modules. The SCR increase in the non-life category is mainly a consequence of the continuous growth in business and changes in retrocession structure for non-life portfolio. The market risk SCR increased due to bearing more currency and spread risk compared to last year. The counter-party default risk SCR rose due to increased recoverables mainly associated with the natural catastrophe events that took place in the summer 2021.

The most material risks based on the year end 2021 SCR calculation are presented in the following table.

Table 16 - Top 3 material SCR risks as of 31 December 2021 (in EUR '000)

Risk Sub-Module	SCR
Non-life underwriting risk	83 588
Market risk	41 339
Counterparty default risk	36 528

The Company has not provided, sold nor re-pledged any collaterals. In addition, the Company does not sell variable annuities, and thus there is no information on guarantee riders and hedging of the guarantees included in this report.

The Company did not enter into securities lending or borrowing transactions, repurchase or reverse repurchase agreements as referred to in Article 4(1)(82) of Regulation (EU) No 575/2013.

C.1 Underwriting Risk

Underwriting risk reflects the risk in the underwriting process including the collection of data, technical assessment of the underlying portfolios, modelling and pricing of the reinsurance contracts and reserving. Heads of Underwriting departments are responsible for the compliance with the underwriting policy and underwriting guidelines of the Company while the governance of quantitative limits, including accumulation control is managed by Corporate Underwriting.

The Company assumes reinsurance on proportional and non-proportional, obligatory and facultative basis. It offers services under the defined lines of business across the property and casualty, personal accident and health and life segments. In relation to underwriting territories, VIG Re focuses its activities on the continental Europe but also being present in East Asia. The underwriting policy, standards and limits are defined in detail in VIG Re reinsurance underwriting guidelines and directives.

The Company adheres to prudent approach towards reinsurance protection. According to reinsurance rules the maximum retention on any assumed risk shall not be higher than 3% of VIG Re's equity. Natural catastrophe retrocession cover is bought at 99.6% percentile of value-at-risk confidence level which is equivalent to 250-year return period. VIG Re's reinsurance panel is carefully chosen in compliance with VIG Re security guidelines.

VIG Re generally does not underwrite business related lines of business which are assessed as significantly exposed to pandemics, such as credit & surety, event cancellation, or travel bonds. However, it is worth mentioning that the Company is exposed to business interruption (BI) and contingent business interruption (CBI) coverages. In relation to the 2021 natural catastrophe events in Europe, namely storms Bernd, Volker and Xero, VIG Re had encountered a significant amount of property losses; however, the impact of those losses to the non-life underwriting risk was mitigated given the retrocession program in place.

Life insurance policies and proportional reinsurance contracts typically provide cover for any cause of death, including pandemics. The impact of the Covid 19 pandemic on the portfolio is analysed on a regular basis and still assessed as immaterial. On the grounds of materiality, mortality and loss rate assumptions have not been adjusted in that respect.

C.1.1 Non-Life and Health Underwriting Risks and Risk Mitigation Techniques

The quantitative risk assessment for the non-life and the NSLT health underwriting risks is performed by making use of an internal model, as the requirements and assumptions of the standard formula do not adequately reflect the Company's risk profile.

The non-life underwriting risk capital requirements calculated by the Company's internal model for 2021 and 2020 are presented in the following table:

Table 17 - Non-Life Underwriting Risk (in EUR '000)

Risk Module	SCR	
	2021	2020
Non-life Underwriting risk	83 588	71 989

The increase in the non-life underwriting risk to EUR 83.6 million in 2021 (2020: EUR 72.0 million) is driven by the increased volumes of net claims best estimates mainly as a result of the growth of the Company's business in 2021 along with an increased retention in property retrocession programs.

The capital requirement for health underwriting risk is presented in the table below:

Table 18 - Health Underwriting Risk (in EUR '000)

Risk Module	SCR	
	2021	2020
Health Underwriting risk	16 912	16 705
SLT health underwriting risk	940	1 034
NSLT health underwriting risk	12 884	12 555
Health catastrophe risk	7 451	7 508
Diversification within health underwriting risk module	-4 363	-4 392

The vast majority of the Company's health business is classified under the non-similar to life techniques module.

It is worth noting that the NSLT health underwriting risk is calculated in the PIM, whereas the SLT and health catastrophe modules are calculated using the standard formula. The capital requirement of NSTL health remained at a similar level compared to prior year as a result of the stable Company's health portfolio.

Premium and Catastrophe Risk

Premium and catastrophe risk arising from future losses and reflects the risk of adverse change in the value of insurance and reinsurance liabilities, resulting from uncertainty of pricing, including related expenses. Unlike single events where each loss is localized in one area and independent of one another, a catastrophe usually gives rise to a large footprint, which is likely to affect a large number of risks. This extends to natural disasters and man-made catastrophes.

In order to manage the risk, the Company has developed and established underwriting guidelines and directives which include defined risk classes and limits. Pricing tools are used in the underwriting process under specific user guide principles which ensure appropriate classification of data received, data quality and adequate pricing. Moreover, the underwriting process is formalized and standardized through an IT workflow system which enables the use of a comprehensive underwriting referral system which is activated by defined thresholds and limits.

This process enables a continuous accumulation control over natural catastrophe events which is reported on regular basis in order to ensure the proper structure of the retrocession protection.

On the quantitative side, the parametrisation of the non-life premium and CAT risk modules as well as the NSLT health premium risk module is performed already during the underwriting process of the individual active reinsurance contracts. This allows the Company to achieve a consistency between PIM outcomes and the view on the risks embedded in the reinsurance contracts at the time when they are underwritten.

Health catastrophe risk is calculated by making use of the standard formula based on the prescribed scenarios for mass accident, pandemic and accident concentration across all countries for medical expense, accident and sickness products.

Non-life concentration risk is stemming from potential lack of diversification across the non-life portfolio. The Company faces underwriting concentration risk in form of natural catastrophe event caused by natural perils and also single risk accumulation from various assumed portfolios. The Company is governed by underwriting guidelines and directives and sets underwriting limits on single exposures in order to mitigate and manage the undertaken risk. Accumulation control for natural catastrophe events is monitored continually with special emphasis during the renewal periods resulting in a comprehensive retrocession program. The Company retroceded approximately 40% of its non-life and health portfolio based on premiums, and half of the retrocession was related to natural catastrophe event coverage in order to mitigate the risk according to the risk strategy. In addition to that, particular retrocession contracts cover single assumed contracts or portfolios of assumed contracts. The portfolios may contain contracts from several reserving segments, several lines of business and proportional or non-proportional business.

Reserve Risk

The Company is exposed to reserve risk, namely the risk that claim provisions are not sufficient to meet future payments of reinsurance liabilities.

The Company manages the risk by establishing rules and procedures described in the internal guidelines of claims management, reinsurance accounting and reserving policies of life and non-life provisions. The procedures are designed and aimed at strengthening the quality, appropriateness, sufficiency and adequacy of the data used in the calculation of technical provisions. Processes and their effectiveness are

assessed annually as part of the internal control system review. It is worth noting that the technical reserves are quarterly assessed and reviewed within the Technical Reserving Committee with emphasis on the large losses and their development.

Annual validation of technical provisions under Solvency II Regulation by an independent person ensures the appropriateness of the methodologies, models and the underlying assumptions used in the calculation of technical provisions.

A conservative approach to the statutory reserving is sought by the Company. Thus, additional case reserves are set up within the Reinsurance Accounting and Claims Management department and if needed revaluated at the Technical Reserving Committee meetings.

Risk Mitigation Techniques

Retrocession is a key risk mitigation technique utilized by the Company. The Company pursues a prudent underwriting philosophy and portfolio management by making use of the diversification benefits when assuming underwriting risks from different lines of business and geographical territories and at the same time monitoring potential concentration risks. This also applies towards its retrocession protection which is prudently structured.

The largest Company's retrocession programme (both by volume and capacity) is the VIG Nat-Cat program which provides coverage against single severe catastrophe events alongside an aggregate annual excess-of-loss cover as a protection against an accumulation of smaller and mid-size events during a year. Particularly in case of major natural disasters in the summer 2021 (Bernd and Volker), retrocession reduced the costs from these events from EUR 336 million gross to EUR 7 million net, after VIG Nat-Cat and all other subsequent retrocession programs.

The Company is further protected by various excess of loss and quota share retrocession contracts for most of the lines of non-life business underwritten such as motor third-party liability, property, motor own damage, marine and aviation, general liability, personal accident. The net combined ratio of the non-life business is further protected by two stop-loss retrocession treaties.

According to VIG Re reinsurance rules the maximum retention on any assumed risk shall not exceed 3% of VIG Re's equity. Natural catastrophe retrocession cover is secured at 99.6% percentile of Value-at-Risk confidence level which is equivalent to 1 in 250-year return period.

The retrocession adequacy and appropriateness are monitored by Actuarial Services and Retrocession department further supported by the partial internal model analyses. Every year the Company performs quantitative and qualitative evaluation of its retrocession protection to optimize and adjust it in line with portfolio development if a need arises.

C.1.2 Life Underwriting Risk

The Company's life portfolio is significantly smaller compared to non-life. The risk capital calculated by the standard formula principles for life underwriting risk is presented in the following table:

Table 19 - Life Underwriting Risk (in EUR '000)

Risk Module	SCR	
	2021	2020
Life underwriting risk	23 002	24 374
Mortality risk	6 316	6 159
Longevity risk	0	0
Disability-morbidity risk	4 721	5 296
Life expense risk	928	1 291
Revision risk	0	0
Lapse risk	17 783	19 631
Life catastrophe risk	5 462	4 319
Diversification within life underwriting risk module	-12 209	-12 323

The slight decrease in SCR is driven mainly by the life portfolio development, mainly by the decrease of the portfolios covering mass lapse risk.

The categories of life underwriting risk which the Company is exposed to, are further described below.

Lapse Risk

The Company is exposed to the risk of lapse rates being higher than expected and also of lapse being lower than expected. It is also exposed to mass lapse, an instantaneous one-off shock lapse event.

The Company calculates the impact of lapse shock in line with Solvency II directive as maximum of predefined lapse scenarios with mass lapse shock being the main driver for lapse capital requirement.

A major source of the mass lapse drop in 2021 is the decrease of the portfolios covering mass lapse risks.

Mortality Risk

Life mortality risk is the risk of loss, or of adverse change in the value of insurance and reinsurance liabilities, resulting from an increase in the mortality rates.

The Company assesses mortality risk through both increase/decrease of mortality rates and through catastrophe scenario mortality increase in line with Solvency II Regulation.

The slight increase in mortality SCR is mostly associated with the development of the Life portfolio.

Morbidity Risk

Life disability-morbidity risk is the risk of loss, or of adverse changes in the value of insurance and reinsurance liabilities, resulting from changes in the level, trend or volatility of disability and morbidity rates.

The decrease of the capital requirement for disability risk is driven by the adjustments to experience assumptions derived from the back-testing process.

Expense Risk

Life expense risk is the risk of loss, or of adverse change in the value of insurance and reinsurance liabilities, resulting from changes in the level, trend, or volatility of the expenses incurred in servicing insurance or reinsurance contracts.

The Company assesses the risk connected with acquisition expenses and future maintenance expenses in line with Solvency II regulation. The experienced decrease of the capital requirement for expense risk is driven by the decrease in the expense assumptions in the life segment.

Revision Risk

Life revision risk is the risk of loss, or of adverse change in the value of insurance and reinsurance liabilities, resulting from fluctuations in the level, trend, or volatility of revision rates applied to annuities, due to changes in the legal environment or in the state of health of the person insured.

Revision risk stemming from non-life annuities is covered in the calculation of non-life underwriting risks.

Risk Mitigation Techniques

In a similar fashion to non-life underwriting, a retrocession is a key mitigation technique utilized by the Company. A prudent retrocession structure has been defined and executed from the beginning of the life active VIG Group business.

The Company has achieved a significant degree of diversification by operating internationally mainly in CEE and German speaking countries, covering range of different lines of business. Except from the VIG business, mostly represented by stable indefinite period treaties, increasing volume of new business is concluded outside of the VIG Group where the risk is mitigated by market diversification and prudent approach. The Company also underwrites new reinsurance treaties in French speaking countries and Asia, which allows for even stronger regional diversification. For entering those new markets, a prudent approach is applied. Diversification over time is also an important factor for risk mitigation.

Life business is underwritten using the mutual agreed conditions. The underwriting conditions are precise defined for every line of business by setting the max sum insured and required medical underwriting procedure.

C.1.3 Risk Sensitivity for Underwriting Risk

Various sensitivities are analysed for the non-life and the NSLT health underwriting risks as part of the PIM Validation process and the ORSA process. Ultimately, the aim of a sensitivity analysis is to identify the most sensitive parameters to ensure the model's robustness and the appropriateness of its implementation.

The analysed parameters comprise calculated input parameters, parameters set by an expert judgement as well as structural aspects of the model, hence all correlation levels are assessed as part of this process.

The most material sensitivity shocks are as follows:

- Increased correlation (+25% per correlation coefficient) for ultimate losses of premium risk which results in decreased Solvency ratio by 8.2 percentage points.
- Increased correlation (+25% per correlation coefficient) for ultimate losses of reserve risk resulting in lower Solvency ratio by 7 percentage points.
- 10% uplift to claims severity for all nat cat exposed contracts which results in 4.11% increased the non-life underwriting capital requirement, which results in 3.1 percentage points lower solvency ratio.
- 5% increase in claims technical provisions best estimates, ultimate losses and standard deviations for reserve risk which results in increased total capital requirements by 1.2%. Due to the decrease in own funds the solvency ratio decreases by 20 percentage points.

In relation to life underwriting risks, the sensitivity analysis was carried out with focus on lapse risk since this is the most significant risk in life underwriting module. Nevertheless, the impact of the scenario is less material within the range of 5-6 percentage points.

C.2 Market Risk

Market risk arises from the level and volatility of market prices of financial instruments. The exposure to market risk can be measure by the impact of predefined movements in the level of market risk factors such as stock prices, interest rates, property prices, credit spreads and FX exchange rates. The market risk is measured by making use of the Solvency II standard formula. VIG Re assess its market risk by Value at Risk measure along with another quantitative risk measures, which in turn defines the maximum potential loss at given probability level and time horizon.

VIG Re invests in compliance with the prudent principles of its investment and risk strategy.

The investments are mainly focused into fixed income instruments as presented in chapter A3. Due to the low yield environment in Eurozone, VIG Re invested higher amount into corporate bonds and high yield government bonds in 2020. The solvency capital requirements for investment funds are calculated using a look-through approach. All investments are accepted within the limits per asset class stated in the approved investment strategy valid for 2021 and also in accordance with the limits set on various aspects of portfolio including rating structure, maturity, industry concentration, localisation and currency.

The risk capital calculated by the standard formula principles of Solvency II market risk is presented below:

Table 20 - Market Risk (in EUR '000)

Risk Module	SCR	
	2021	2020
Market risk	41 339	32 697
Interest rate risk	6 328	6 872
Equity risk	4 542	6 522
Property risk	3 669	1 864
Spread risk	23 486	19 272
Market risk concentrations	4 801	6 603
Currency risk	16 547	11 183
Diversification within market risk Module	-18 034	-19 619

The main increase is identified the spread risk due to the acquisition of corporate bonds in portfolio with higher durations along with temporary increased currency gaps mainly in JPY and CZK.

Figure 8 below shows the percentage of market risk allocation for each risk sub-module as calculated by the Solvency II standard formula (before diversification).

Figure 8 - Composition of Market SCR 2021



C.2.1 Key Risks and Risk Mitigation Techniques

Interest Rate Risk

Interest rate risk arises from all assets and liabilities sensitive to changes in the term structure of interest rates or in the volatility of interest rates. The interest rates in Eurozone changed their shape compared to prior year. In general, these have steepened meaning the period over which rates are negative is significantly shorter compared to year end 2020.

The Company's exposure to interest rates arises primarily from the bond portfolio (as bond values are susceptible to changes in interest rates) on the asset side, and the settlement of future claims (as the discount rates applied to claims settlement projections are impacted by interest yield curves) on the liability side. The capital requirement for interest rate risk remained similarly to year end 2020. It is worth noting that unlike last year, this year's capital requirement is derived from the downward shock given a less significant impact of the floor under the downward shock since the rates remained negative over a shorter period in comparison with the prior year ends. We also noticed an improvement in asset-liability matching stemming from increased liquid assets which also reduced the capital requirement.

Equity Risk

Equity risk arises from the level or volatility of market prices for equities. The Company is exposed to equity risk from investment funds and the risk decreased due to decreased equity exposure as a result of less equity funds in the portfolio compared to year end 2020.

Property risk

Property risk arises from the sensitivity of assets to the level or volatility of the property market prices. VIG Re retains a relatively minor exposure to the property risk, mostly stemming from real estate funds' look through approach.

Spread Risk

Spread risk arises from the sensitivity of the value of assets and financial instruments to changes in the level or in the volatility of credit spreads over the risk-free interest rate term structure. Credit spreads are typically narrower for high rated securities and shorter durations. The Company is exposed to spread risk from the corporate bond portfolio with an elevated average duration compared to last year resulting in increased spread capital requirements.

Currency Risk

The Company's reporting and main transactional currency is Euro, which comprises approximately 90% of the Solvency II balance sheet. Other material national currencies are from Turkey, Czech Republic, Poland, Japan and USA. The currency gap is actively monitored and managed within the asset-liability management. The Company strives to have a close position according to its investment strategy.

Concentration Risk

Concentration risk is the risk stemming either from a lack of diversification in the asset portfolio or from large exposure to default risk by a single issuer of securities or a group of related issuers. This extends to assets considered in the equity, spread risk and property risk, and excludes assets covered by the counterparty default risk. Given the well diversified portfolio of the Company, concentration risk remains relatively low.

The Company issues the Investment Strategy on annual basis in order to achieve a proper balance between invested assets and technical liabilities while keeping a balanced risk/return-profile. The strategy is approved by the Supervisory Board and includes the strategic asset allocation comprising minimum and maximum limits for each defined asset class, enabling a reasonable but limited potential space to adapt according to short- and mid-term market expectations, but also to limit the risk related to different industries or groups.

The compliance of these limits is monitored by Mid Office and Asset Management departments of Kooperativa and reported monthly to VIG Re's Risk Management function, Board of Directors and quarterly to the Supervisory Board.

The goal of the investment strategy is to optimize the portfolio's risk-return profile while taking into account various risk parameters. Risk management related to assets is in line VIG Re Guidelines related to investments and is coordinated by VIG Asset Risk Management department in close cooperation with Risk Management function of VIG Re.

Counterparties are selected by taking into account the credit rating and reputation of each entity. Credit ratings are used as a way of properly identifying and managing the risk attached to a counterparty and the Company ensures only counterparties with a high enough credit rating are used.

The Company invests only in types of assets, for which it can recognize, measure, monitor, manage and control the related risks accordingly by own means. Regular reports are delivered regarding the limits monitoring of investment policy. In case of investment in new instruments the impact on solvency capital requirement is assessed. The main goal of the investment policy is to reach the planned investment result while keeping a balanced risk/return-profile and taking into account constraints given by asset risk management requirements.

Only approved financial instruments may be used for transactions. Only those instruments may be approved, which can be mapped, evaluated, monitored and professionally used by own means in terms of quality and quantity of personal staff and appropriate systems. Accounting and balance sheet regulations, especially regarding evaluation units as well as the quantification and steering of related risks of single investments have to be clarified and recorded beforehand.

All counterparties or issuers of financial transactions or any investments (with payment and settlement risks) shall be pre-agreed by defining general or individual limits. The validation of the creditworthiness and monitoring of limits is performed by persons independent from trading.

Keeping substantial share of fixed income investments (bonds and loans) in the portfolio leads to stable expected returns and generally lower volatility. This measure has been thoroughly taken into account and is reflected in the investment strategy.

C.2.2 Risk Sensitivity for Market Risk

The Company carries out stress and scenario testing as a part of the ORSA process, which includes stress testing and sensitivity analysis for market risk, with emphasis on interest rate risk on both impacts of potential decrease and increase of the interest rate curve by 100 basis points. Movements of interest rates affect both in own funds and SCR particularly in PIM modules resulting in 6-7 percentage points deviation rather symmetrically for the two scenarios.

The adverse scenario of 20% drop in equity market value will respectively decrease Own funds and partially SCR, nevertheless the impact on the Solvency position is immaterial less than 2 percentage points.

C.3 Credit Risk

Credit risk refers to the risk of loss or of adverse change in the financial situation, resulting from fluctuations in the credit standing in relation to the counterparty default, spread risk or concentration risk. The main sources of credit risk can be categorised as follows:

- Investments,
- Reinsurance recoverables,
- Deposits to cedants,
- Insurance and reinsurance receivables
- Cash at bank.

It is worth noting that the spread and concentration risks are further discussed in the previous chapter C.2 Market risk.

C.3.1 Key Risks and Risk Mitigation Techniques

Counterparty Default Risk

Counterparty default risk is defined as risk of loss, or adverse change in the value of assets and financial instruments due to unexpected default, or deterioration in the credit standing, of counterparties and debtors over the forthcoming twelve months. The scope of the counterparty default risk for VIG Re includes risk-mitigating contracts, such as reinsurance arrangements, receivables from intermediaries, as well as any other credit exposures which are not covered by spread risk.

For the purpose of calculating the capital requirement for counterparty default risk, credit exposures are broken down into two types. Type 1 exposures are those where diversification is low and the counterparty is likely to be rated. Type 1 exposures comprise exposures in relation to risk-mitigation contracts, cash at bank and deposits and other financial commitments.

Type 2 exposures are all credit exposures that are not covered in the spread risk sub-module that are not Type 1. They tend to be well diversified towards likely non-rated exposures. Some of the exposures that fall under Type 2 are receivables from intermediaries and ceding insurance companies.

The Company is exposed to both Type 1 and Type 2 exposures as set out in the Solvency II regulation. The capital requirement is calculated by making use of the standard formula principles for counterparty default risk.

Table 21 - Counterparty Default Risk (in EUR '000)

Risk Module	SCR	
	2021	2020
Counterparty default risk	36 528	28 196
Type 1 exposures	26 249	16 740
Type 2 exposures	12 451	13 376
Diversification within counterparty default risk module	-2 172	-1 920

The increase in the capital requirement for counterparty default risk is predominantly attributed to a significantly larger amount of retrocession recoverables associated with the natural catastrophe events in Europe that took place in 2021.

The Company limits its potential liability from reinsurance business by passing on some of the risks it assumes to the international reinsurance market (retrocession). The reinsurance coverage is diversified over a large number of different international reinsurance companies that VIG Re assesses with adequate creditworthiness, to minimize the credit risk due to the insolvency of the reinsurers. The Company strictly adheres to the issued security guidelines, limiting the counterparties which VIG Re can conclude retrocession contracts with.

Deposits to ceding undertakings are monitored by the Corporate Underwriting and the Risk Management functions. Depending on the treaty wording, counterparty default risk may arise from these arrangements subsequently taken into account in the counterparty risk calculation.

The counterparty risk arising from financial instruments including cash and term deposits is governed by the investment strategy where limits per tenor and bank are defined. Any new counterparty financial institution is subject to VIG Group approval.

C.3.2 Risk Sensitivity for Credit Risk

The Company carries out stress and scenario testing as a part of the ORSA process, which includes sensitivity analysis for credit risk by deteriorating the credit standing of both reinsurance counterparties in the scope of the counterparty default risk as well as investment counterparties affecting the spread risk. Given the high credit quality of the retrocession panel, downgrading of reinsurance counterparties by one credit notch does not have a material impact on the Company's capital requirements. The solvency ratio is decreased by 6 percentage points under the scenario of 100bps increase in the credit spread of corporate bonds.

The default of retrocession counterparties with material exposure in retrocession recoverables might possibly lead to significant losses; hence, this risk is managed by entering into retrocession contracts with highly credit rated counterparties.

C.4 Liquidity Risk

Liquidity risk refers to the risk of the Company being unable to realize investments and other assets in order to settle their financial obligations when those become due. The risk is managed by the appropriate duration matching between the financial investment portfolio and reinsurance commitments.

C.4.1 Key Risks and Risk Mitigation Techniques

The Company regularly performs assessment of its liquidity position, by processing short-term and mid-term overviews of expected inflows and outflows as part of its asset liability management activities. This allows the Treasury department to manage properly funds of the Company, in order to ensure that sufficient funds are available to fulfil the liabilities.

The risk is governed by the Investment Strategy which defines a liquidity buffer comprising highly liquid securities and cash. More specifically, at least EUR 10 million shall be held in highly liquid investment assets to serve as liquidity cushion (cash, deposits, T-bills, money market funds, floating rate or short-term fixed rate bonds) along with other assets ready to cover possible cash-flow needs and deliver needed return. Hence, the risk is assessed to be low.

C.4.2 Expected Profit Included in Future Premiums (“EPIFP”)

Expected profit included in the future premiums as of 2021 year end amounted at EUR 64.1 million (2020: EUR 68.2 million) for non-life and health portfolio.

The EPIFP for Life portfolio amounted at EUR 22.4 million as of 2021 year end (2020: EUR 14.5 million).

The values can also be found in S.23.01 Quantitative Reporting Template.

C.4.3 Risk Sensitivity for Liquidity Risk

The risk is assessed for extreme scenarios as part of the ORSA process combining nat cat events alongside changes to the payment patterns. Nonetheless, the Company has retained a significant volume of investments on highly liquid securities which can support the liquidity needs in such a case. As a result, the recent nat cat events did not challenge the Company’s liquidity.

C.5 Operational Risk

Operational risk is resulting from the insufficiency or failure of internal processes, employees and systems, or caused by external occurrences.

Unlike prior year, the capital requirement calculated by the standard formula principles for the operational risk results from the provision-based risk component.

Table 22- Operational Risk (in EUR ‘000)

Risk Module	SCR	
	2021	2020
Operational risk	23 908	17 572

The increase in the capital required is due to the increase in the gross technical provisions excluding the risk margin due to the nat cat events which in turn caused the provision risk component exceeding the premium based risk component for the first time in the history of VIG Re.

C.5.1 Key Risks and Risk Mitigation Techniques

The Company follows VIG guidelines to ensure its efficient and economic operation. The Company seeks to maintain functional key processes as well as assets supporting the aim to provide sustainable reinsurance services by defining strict procedures, controls and emergency plans.

The operational risk according to the standard formula is derived from the amounts of gross earned premiums and gross best estimates. This assessment is deemed not to provide a deep understanding of the underlying sources and associated effects of operational risk. With that being said, the operational risk is further divided into further sub-categories and additionally assessed qualitatively through the Internal

Control System in accordance with the Group guidelines in order to obtain a more precise risk profile. The operational sub-risk categories are as follows:

- model and data quality risk,
- project risk,
- process and organizational risk,
- human error risk,
- business disruption risk,
- know-how concentration risk,
- insufficient human resources,
- hardware and infrastructure,
- IT software and security,
- IT development,
- compliance risk.

C.6 Other Material Risks

C.6.1 Other Risks

Among other risks the Company identifies strategic risk, of adverse business development related to inappropriate business and investment decisions, or to inadequate communication and implementation of goals, or to a lack of adjustment capacity to changes in the economic environment, or to conflicting business objectives.

The Company has introduced the new Strategy 2025 in line with the risk strategy, taking into consideration various possible scenarios on the further macroeconomic environment, the impact on the (re-)insurance industry as well as the risk and solvency position of the Company.

VIG Re is also exposed to reputational risk which is defined as the risk of adverse business development associated with damage to the Company's reputation. A loss of reputation can disrupt the confidence of customers, investors, or employees in the Company, and thus may lead to financial damage. To mitigate the risk, recruitment of qualified personnel is applied and all areas that could potentially affect the Company's reputation are monitored.

On 3rd November 2021, Standard & Poor's Global Ratings confirmed its long-term public issuer credit rating of "A+" and financial strength rating of "A+" with a stable outlook for VIG Re, affirming the same rating VIG Re has secured ever since its foundation.

C.7 Any Other Information

There is no other information to be disclosed in this chapter.

VALUATION
FOR SOLVENCY
PURPOSES



VIG Re prepares its financial statements in accordance with the International Financial Reporting Standards (IFRS) and their interpretations as adopted by the International Accounting Standards Board (IASB) and the European Union (EU) in accordance with the IAS Regulation (EC 1606/2002). The differences in valuation of assets and liabilities classes under IFRS and Solvency II purposes are stated in the relevant sub- chapters below.

D.1 Assets

As of 31 December 2021, the Company held the following assets (in EUR '000):

Table 23 - Assets Comparison (in EUR '000)

Assets	Solvency II		IFRS	
	2021	2020	2021	2020
Deferred acquisition costs	0	0	9 608	10 270
Intangible assets	0	0	2 478	1 793
Deferred tax assets	0	0	10 727	3 444
Property, plant & equipment held for own use	2 548	2 952	2 548	2 952
Investments, thereof:	501 116	477 926	502 354	476 978
Holdings in related undertakings, including participations	8 663	6 648	14 778	12 770
Equities	1 173	1 337	1 173	1 337
Equities - listed	0	479	0	479
Equities - unlisted	1 173	858	1 173	858
Bonds	351 177	338 245	346 300	331 175
Government Bonds	206 390	217 522	201 512	210 724
Corporate Bonds	144 787	120 723	144 787	120 452
Collective Investments Undertakings	140 102	131 696	140 102	131 696
Deposits other than cash equivalents	0	0	0	0
Assets held for index-linked and unit-linked contracts	8 480	6 801	8 480	6 801
Loans & mortgages	12 374	7 701	12 031	7 161
Reinsurance recoverables	476 474	201 840	554 242	278 425
Non-Life and Health similar to Non-Life	472 058	196 243	548 672	273 757
Non-Life excluding Health	452 437	179 128	525 837	254 993
Health similar to Non-Life	19 622	17 115	22 835	18 763
Life and Health similar to Life, excluding Health and index-linked and unit-linked	4 416	5 597	5 570	4 668
Health similar to Life	0	0	0	0
Life excluding Health and index-linked and unit-linked	4 416	5 597	5 570	4 668
Life index-linked and unit-linked	0	0	0	0
Deposits to cedants	105 828	116 137	92 565	94 545
Insurance & intermediaries receivables	109 837	84 031	109 837	84 031
Reinsurance receivables	104 990	38 034	104 990	38 034
Receivables (trade, not insurance)	6 672	2 711	6 672	2 711
Cash and cash equivalents	60 754	44 817	60 754	44 817
Any other assets, not elsewhere shown	353	391	353	391
Total assets	1 389 427	983 341	1 477 639	1 052 353

D.1.1 Deferred Acquisition Costs

In the financial statements, deferred acquisition costs represent the proportion of acquisition costs incurred and revenue received that corresponds to the unearned premium reserve.

Solvency II valuation is based on an estimation of future cash flows and deferred acquisition costs represent a cash outflow that occurred in the past. The (future) premiums may indeed include an expense charge to cover these acquisition costs; however, those are incorporated in the technical provision cashflows.

Therefore, deferred acquisition costs (gross and reinsurance share) are stated with zero in Solvency II balance sheet.

D.1.2 Intangible Assets

Intangible assets comprise acquired portfolios, purchased licenses or brand names. For the financial statements these assets are valued at their acquisition costs less accumulated amortization and impairment losses. Under Solvency II all intangible assets are valued at zero as none of the assets can be regarded as sellable on active market.

D.1.3 Deferred Tax Assets

Similarly to IFRS, deferred taxes are calculated based on temporary differences between Solvency II and valuations of assets performed for tax purposes according to the national tax laws. In accordance with Solvency II and IAS 12 regulations, only deferred tax assets dependent on future taxable income are allowed for recognition. Differences, which will not reverse in future periods are permanent differences do not lead to deferred taxes. Deferred taxes are not discounted and are shown in net value as net deferred tax liabilities in Solvency II balance sheet.

D.1.4 Property, Plant & Equipment Held for Own Use

IFRS value, measured at cost less accumulated depreciation and impairment losses. Cost includes expenditures directly attributable to the acquisition of the asset. When parts of an item of property and equipment have different useful lives, they are accounted for as separate items (major components) of property and equipment. The value is taken for Solvency II valuation as well.

According to IFRS16, right of use assets are included in the total value of EUR 1 696 thousand for IFRS and also Solvency II valuation. This is made up of the three rented premises for Headquarters and both branches.

D.1.5 Investments

VIG Re owns 100% in Wiener Re Serbia and a 3.13% stake in VIG Fund, a.s. For the financial statements, participations are valued at acquisition cost less impairment.

The participation in Wiener Re valued at EUR 6 759 thousand in IFRS balance sheet, is valued at nil in Solvency II.

Financial Assets

Financial assets include government and corporate bonds and collective investment undertakings (investment funds). Financial assets are measured at fair value for Solvency II purposes even if measured at amortised cost in the IFRS balance sheet. Fair value is based on market quotations of the individual instruments – government and corporate bonds and collective investments – on liquid markets. As at the end of 2021, VIG Re held only a limited amount of bonds where no market quotation was available, representing 6% of the investment portfolio.

Using the market prices explains the differences in valuation of the bonds – for financial statements, part of the bond portfolio for which VIG Re has the positive intent and ability to hold these bonds to their maturity is classified as held-to-maturity and thus valued at amortized costs.

D.1.6 Reinsurance Recoverables

In the financial statements, the ceded share of reinsurance liabilities is valued in accordance with contractual retrocession arrangements. The creditworthiness of each counterparty is considered when assessing the carrying amount of the assets. Any impairment loss is recognized in profit and loss.

Under Solvency II, the reinsurance recoverables are calculated as the best estimate of the amount that the Company expects to receive from the reinsurance arrangements (taking into account the cash-flows related to the arrangements and the time value of money), adjusted by the probability of the counterparty default. Reinsurance recoverables are segmented into non-life (including NSLT health), life (including SLT health) and life unit-linked.

Best Estimate Retrocession Recoverables

The characteristics of the retrocession exclude the use of the development triangles. The development triangles are not adequately stable due to the combination of different types of retrocession and approximations needed to split retrocession cash flows per reserving segment.

The implemented methodology uses a simplified approach, described in Guidelines on technical provisions, guideline 79 and 80, published by EIOPA. The calculation of retrocession recoverable uses ratios of an expected retrocession share on gross cash flows which are described in chapter D.2 Technical Provisions.

For life portfolio, the characteristics of the retrocession recoverables follow directly features of the active reinsurance contract and are modelled directly in the life actuarial models.

Counterparty Default Adjustment

The Company's retrocession panel is diversified over a large number of high rated international reinsurance companies that the Company assesses with adequate creditworthiness, to minimize the credit risk due to their insolvency, hence the result is not material. The calculation methodology is based on the simplification described in Article 61 of Delegated Acts.

D.1.7 Deposits to Cedants

These balances represent deposits in ceding companies in order to cover the reinsurance liabilities (technical provisions) of the Company towards these clients. For deposits related to non-life and NSLT health contracts, the Company makes use of the IFRS valuation for Solvency II purposes as well.

Life segment deposits might be represented by different types of reserves depending on each specific treaty conditions – reinsurance premium reserve, UPR and claims reserves. Deposited reserves are projected by the actuarial model from portfolio information by applying actuarial methods and a set of demographic and economic assumptions. The Company might receive an investment income generated by fixed interest on its deposited reserves on an annual basis. Under Solvency II, all deposits to cedants and investment incomes from these deposits are valued at present value.

D.1.8 Insurance & Intermediaries Receivables

Insurance and Intermediaries receivables represent amounts from ceding insurance undertakings and/or reinsurance brokers, which have not been accounted for in the projected cash flows used for the calculation of technical provisions.

The fair value for Solvency II is represented by the IFRS value.

D.1.9 Reinsurance Receivables

Amounts from reinsurers linked to ceded reinsurance which are not included in reinsurance recoverables. This includes, but is not limited to, amounts receivable from reinsurers that relate to settled claims of ceding undertakings or commissions.

The fair value for Solvency II is represented by the IFRS value.

D.1.10 Receivables (Trade, Not Insurance)

Amounts from employees, business partners other than insurance or reinsurance undertakings for their services, or other persons.

The fair value for Solvency II is represented by the IFRS value.

D.1.11 Cash and Cash Equivalents

Cash comprises cash on hand and demand deposits with banks and other financial institutions. Cash equivalents are short-term, highly liquid investments that are readily convertible to known amounts of cash and subject to an insignificant risk of changes in value.

The fair value for Solvency II is represented by the IFRS value.

D.1.12 Any other Assets, not Elsewhere Shown

These assets are valued at fair value by discounting expected cash flows using a risk-free rate. However, book value as per IFRS may be used as a proxy to the fair value for Solvency II balance sheet purposes where the impact of discounting is not material because the balances are either of a short-term nature or not material.

D.2 Technical Provisions

D.2.1 Technical Provisions – Non-Life and Health Non-Similar to Life Underwriting Techniques

In 2021, the Company experienced a significant growth in the values of technical provisions on gross level as a result of portfolio growth along with reported losses associated with the natural catastrophe events in Western and Central Europe having a main impact on the property non-proportional line of business.

Table 24 - Technical Provision (in EUR '000)

SII Line of Business	2021			2020		
	Best estimate	RM	Technical provision	Best estimate	RM	Technical provision
Medical expense proportional	3 495	109	3 603	4 244	115	4 359
Income protection proportional	17 277	2 471	19 748	18 019	2 809	20 827
Workers' Compensation proportional	66	5	71	27	1	28
Health non-proportional	18 274	504	18 778	12 124	585	12 710
Motor vehicle liability proportional	45 730	1 932	47 662	38 197	1 772	39 969
Other motor proportional	6 333	238	6 572	4 817	135	4 952
Marine, aviation and transport proportional	6 829	198	7 027	6 273	175	6 447
Fire and other property proportional	155 358	2 707	158 065	105 526	2 536	108 062
General liability proportional	20 706	888	21 594	20 404	1 108	21 513
Credit and suretyship proportional	842	22	865	683	12	695
Legal expenses proportional	66	3	68	42	1	43
Miscellaneous proportional	10	0	10	1	0	1
Casualty non-proportional	203 844	15 718	219 561	169 709	13 719	183 429
Marine, aviation and transport non-proportional	8 773	456	9 229	9 665	411	10 076
Property non-proportional	301 068	4 031	305 098	69 600	2 971	72 571
Total	788 672	29 281	817 952	459 329	26 352	485 682

D.2.1.1 Recognition of the Liabilities, Segmentation into Homogeneous Risk Groups

The portfolio of the Company contains reinsurance contracts which can cover multiple risks and lines of business on occurrence year, underwriting year and clean-cut basis.

Coverage period of majority of the treaties is 12 months with most being underwritten in advance during the fourth quarter. This means that VIG Re is committed to them as at the valuation date, but insurance coverage has not yet commenced ("written but not yet incepted business"). For a year end valuation this generally includes the 1st January renewals for the coming year.

The reinsurance liabilities are segmented into the Solvency II lines of business (SII LoBs). VIG Re splits the particular SII LoBs further into homogenous risk groups ("segments"), based on their homogeneity and ability to support sound claim development analysis (robustness of final segments).

D.2.1.2 Actuarial Methodologies and Assumptions Used in the Calculation of the Best Estimate

The basic split of the gross best estimate calculation is to claim and premium provisions. VIG Re's data is collected on an underwriting year basis, which combines claim and premium provisions, hence a split to previous underwriting years and the next underwriting year is used. The analysis for previous underwriting years is further split into two parts – a calculation of the ultimate volumes of the cash flows for individual underwriting years and an estimation of the distribution of those cash flows in time, i.e. estimation of patterns related to individual cash flows.

Previous Underwriting Years

Previous underwriting years are captured in the development triangles with underwriting years as the origin periods and development periods linked to the financial posting date, i.e., date when the accounting records were created. The basis for the calculation is the development triangles of claims paid, claims incurred, premium earned and commissions incurred.

For the calculation of ultimate volumes of future cash flows the following methods implemented in ResQ are suitable for the portfolio of VIG Re:

- Development factor methods (DFM)
- Ultimate ratio method
- Bornhuetter Fergusson method (BF)
- Weighted averages of methods above, e.g. Benktander method (combination of DFM and BF methods)

In the case of claims, the described methods can be applied either on the claims paid or claims incurred. The choice of the final triangle depends on characteristics of the reserving segment.

For the calculation of time distribution of future cashflows, the following cash flow patterns are used in VIG Re's Best estimate calculation:

- Premium pattern,
- Commission pattern,
- Pattern of claims paid,
- Pattern of claims incurred.

Operating expenses are expected to have the same distribution over time as premium, i.e. premium pattern is used also for operating expenses.

The estimation of the patterns is based on the development triangles with underwriting years as origin periods. The resulting patterns are therefore patterns for cash flows relating to whole underwriting years.

The underwriting year patterns capture what proportion of the ultimate cash flows for an individual underwriting year is realised with a particular delay from this underwriting year. The delay is measured in years and is based on calendar/accounting years. The first element of the pattern corresponds to the cash flows realised in the same calendar year as the underwriting year. The cash flows originating in one underwriting year may contribute to cash flows originating in more than one accident year. The same is true also for underwriting year patterns and accident year patterns. Since the development triangles and patterns based on underwriting years do not contain information about the split of cash flows to accident years, this split must be estimated to divide TP into claim and premium provisions.

Next Underwriting Year

The calculation of the best estimate for the next underwriting year, contributing only to the premium provision, is based on the following inputs:

- Premium cash flow
 - expected ultimate premium volume of the reserving segment for the next underwriting year within contract boundaries as at the valuation date,
 - expected pattern of earned premium.
- Claim cash flow
 - ultimate claim ratio of the reserving segment for the next underwriting year,
 - expected pattern of claims paid.
- Commission cash flow
 - ultimate commission ratio of the reserving segment for the next underwriting year,
 - expected pattern of commissions incurred.
- Admin cash flow
 - admin ratio for the next underwriting year.

Annuities

The portfolio assumed to contain mostly annuities is contained in two separate reserving segments. The claims patterns are based on claims incurred for these segments. The reason is that the claim provisions of reported annuity claims are calculated using Life actuarial techniques by cedants. The future expected claims are projected, taking into account biometric parameters, and discounted. The application of claims incurred pattern as claims pattern in TP calculation in VIG Re respects that the reported annuity claim provisions are already discounted. What needs to be additionally considered, is the delay until the reporting of the claims. This is captured by the projection of claims incurred and their discounting.

Split to Premium and Claim Provision

The calculation of the Best estimate per underwriting year leads to the projection of future cash flows per underwriting year. These cash flows may belong to both claim and premium provisions, therefore it is necessary to split cash flows accordingly.

These cash flows, split into premium and claims provision, are discounted using the relevant risk-free rates for the currencies of the country of the cedants, as published by EIOPA. The Company does not apply matching adjustments, volatility adjustments or transitional risk-free term structure or transitional deduction.

Options and Guarantees

VIG Re does not have any options or guarantees in non-life reinsurance, therefore their value is equal to zero.

Lapse Rate

The concept of lapse rate is not directly applicable in the context of reinsurance business. It is de facto very remote due to the nature of reinsurance business, and it is not modelled explicitly in the calculation of technical provisions.

Data Quality

The key inputs to Technical Provisions calculation are the historical cash flows and changes in RBNS, contained in the accounting system, and expected premium of particular reinsurance treaties and sections to be ceded to VIG Re.

Historical consistency of data is always checked while the consistency with the accounting data is achieved by automated processes.

The external data quality of the accounted values is driven by setting of communication with cedants. The accounted values are recorded with different frequency for different cedants and often based on estimates which are calculated by both VIG Re and cedants.

Economic Assumptions

VIG Re uses risk free interest rates published by EIOPA, without any adjustments. Exchange rates used for the valuation are provided by the VIG group or other reliable sources like central banks. Other economic statistics like inflation, unemployment rate and GDP are monitored and considered as a supporting information for the portfolio segmentation.

Non-Economic Assumptions

The key non-economic assumption for VIG Re is the portfolio segmentation. VIG Re uses a more granular segmentation compared to Solvency II lines of business which is based on the key portfolio characteristics such as claims, premiums, commissions, operating expenses and cash flows with reinsurers.

D.2.1.3 Calculation of the Risk Margin

The risk margin ensures that the value of the technical provisions is equivalent to the amount that reinsurance undertakings would be expected to require in order to take over and meet the reinsurance obligations. VIG Re calculates the risk margin in accordance with the Article 37 of the Commission Regulation 2015/35.

For the estimation of future SCRs, VIG Re uses the method based on projected elements of the SCR per risk sub-module and LoB based on the selected drivers. The obtained projections are then aggregated using the relevant correlation matrices, discounted by risk-free interest rates and multiplied by cost of capital rate 6%.

D.2.1.4 Level of Uncertainty Associated with the Value of Technical Provisions

The main source of uncertainty is still relatively short history of VIG Re. The Company started writing its business in 2009 and therefore construction of only relatively short development triangles is possible. This is an issue mainly for the long tail non-proportional business as the tail factors for deriving the cash flow patterns need to be developed only with a high degree of subjectivity using an expert judgement. This segment is significant in the portfolio, based on net best estimates. The estimated development factors in the triangles are also subject to a higher degree of uncertainty due to the nature of reinsurance business, this concerns especially to all non-proportional reinsurance SII LoBs.

Sensitivities of best estimate components (claim and premium provisions) to the predefined stresses can be found in the table below. These shocks were picked as a sufficient illustration of the uncertainty associated with the value of technical provisions.

Table 25 - Sensitivities 2021 (in EUR '000)

Assumption change	CP, gross	CP, net, after CDA, PAXL	PP, gross	PP, net, after CDA	Total BE, net
Basis scenario	832 311	343 979	-43 640	-27 366	316 613
Written premium up +5%	832 311	343 979	-46 843	-29 407	314 572
Written premium down -5%	832 311	343 979	-40 436	-25 324	318 655
Claims Paid up +5%	868 872	357 983	-19 195	-13 002	344 981
Claims Paid down -5%	795 751	329 975	-68 085	-41 730	288 245
RFR shock up (+100 bps)	798 212	329 308	-55 572	-32 914	296 394
RFR shock down (-100 bps)	850 436	351 631	-37 558	-24 738	326 893

D.2.1.5 Solvency II and IFRS Valuation Differences of Technical Provisions

The technical provision created for the purposes of Solvency II differs from the technical provision created for the purposes of accounting under IFRS mainly due to the following reasons:

- under Solvency II discounting is applied for all lines of business,
- under IFRS the Company builds an additional prudence IBNR,
- recognition of anticipated profits on unearned premiums under Solvency II (in respect of premium best estimates),
- adding of risk margin to the best estimates under Solvency II,
- calculation methods are applied differently for Solvency II and accounting purposes.

Within the premium provision, best estimates allow for the anticipated profits embedded in the premium receivables, which in turn reduces the level of technical provisions.

Table 26 - IFRS and Solvency II Technical provisions 2021 (in EUR '000)

Lines of business	IFRS		Solvency II		
	Outstanding claims provisions	Unearned premiums provision	Claim BELs	Premium BELs	Risk margin
Non-Life	862 154	16 237	780 968	-31 409	26 192
HNSLT	57 680	-848	51 343	-12 231	3 088
Total	919 834	15 389	832 311	-43 640	29 281

IFRS technical provisions comprise unearned premiums provision and provision for outstanding claims.

- The provision for unearned premiums comprises that part of gross premiums written attributable to the following financial year or to subsequent financial years, computed separately for each reinsurance contract using the pro rata temporis method.
- The provision for outstanding claims represents the total estimated ultimate cost of settling all claims arising from events that occurred up to the end of the financial year and are covered by reinsurance contracts, whether reported or not, less amounts already paid in respect of such claims, including the related internal and external claims settlement expenses.

Solvency II technical provisions consist of best estimates of future liabilities (BELs) and risk margin. The best estimate is defined as expected present value of future cash-flows taking account of the time value of money, using the relevant risk-free interest rate term structure.

- Provisions for claims outstanding relate to the cashflows in respect of claims events occurring before or at the valuation date, whether the claims arising from those events have been reported or not. The cashflows projected comprise all future claims payments, often described as
 - Claims Outstanding (case reserves);
 - Incurred But Not Reported claims ("IBNR");
 - Incurred But Not Enough Reported claims ("IBNER").

Claims provisions cashflow projections should also include all claims management and claims administration expenses arising from these events.

- Premium provisions relate to claims events occurring after the valuation date and during the remaining in-force coverage period of policies. The cashflow projections should comprise all future claims payments and claims management expenses arising from those events, cashflows arising from ongoing administration of the in-force policies and expected future premiums stemming from existing policies. As with claim provisions, the valuation should take account of the time value of money and the best estimates must not include margins.
- Risk margin has been considered to ensure that the value of the technical provisions is equivalent to the amount that would be expected to be paid to a third party reinsurance company in order to take over and meet the insurance obligations of the Company.

D.2.2 Technical Provisions – Life and Health Similar to Life Underwriting Techniques

The following table gives an overview of gross life technical provisions, together with their comparison with the IFRS value.

Gross technical provisions as at 31.12.2021 are presented below:

Table 27 - Gross technical provisions 2021 (in EUR '000)

Lines of business	IFRS	Solvency II	
	Life technical provisions	BELs	Risk margin
Life excluding Unit-/Index-linked and HSLT	88 494	57 335	11 263
Unit-/Index-linked*	8 480	8 782	1 628
HSLT	0	-2 163	1 452
Total	96 974	63 954	14 343

Gross technical provisions as at 31.12.2020:

Table 28 - Gross Technical Provisions 2020 (in EUR '000)

Lines of business	IFRS	Solvency II	
	Life technical provisions	BELs	Risk margin
Life excluding Unit-/Index-linked and HSLT	87 202	68 039	14 592
Unit-/Index-linked*	6 801	7 405	1 588
HSLT	0	-2 100	1 494
Total	94 003	73 344	17 674

D.2.2.1 Recognition of Contracts, Segmentation into Homogeneous Risk Groups

All reinsurance treaties are divided into the relevant Solvency II LoBs on reinsurance contract level. The vast majority of life technical provisions is segmented under the with profit participation LoB.

The Company doesn't apply contract boundaries because the cancellation of reinsurance treaty relates only to underlying business signed during the upcoming underwriting year, while existing business cancellation is not at the free will of the cedent or the Company.

For most of the elements of the technical provisions main coverage and riders are unbundled and modelled separately.

D.2.2.2 Actuarial Methodologies and Assumptions Used in the Calculation of the Technical Provisions

Methodology

Technical provisions are calculated as a sum of a best estimate liabilities and risk margin. Projection of cash-flows is performed by making use of the life actuarial model.

Life actuarial model is also utilised in setting of the Solvency II value of deposited reserves as part of asset valuation.

Risk margin is calculated in line with VIG Re's guidelines on the calculation of the risk margin under SII. The Company applies a simplification and projects the SCR based on relevant risk drivers to be used for projection of individual sub-modules of the SCR. To obtain the annual costs the Company uses the prescribed cost of capital rate of 6%.

Assumptions

The primary insurers' portfolio data and non-economic assumptions are updated on an annual basis. Economic assumptions are updated on a quarterly basis and are provided by VIG Group.

Assumptions and parameters utilised by the actuarial model are also reviewed annually. The long-term principle is applied while setting up best estimates of assumptions. The Company performs a set of analyses with a view to justify assumptions setting, including the back-testing and sensitivity analyses in order to quantify the impact of possible volatility in assumptions.

Key Options and Guarantees

The Company does not have any options or guarantees in its life reinsurance portfolio and therefore their value is set to zero.

No future management actions nor future discretionary benefits are managed in line with the actual Company's approach for life portfolio.

Policyholder behaviour does not need to be considered in the best estimate calculation due to:

- the cedants are not allowed to cancel treaties wilfully,
- behaviour of policyholders is already captured in lapse rates.

Lapse Rates

For the set up of lapse rates, the principle of long-term assumptions is followed. Lapse rates are updated on an annual basis following the lapse experience of underlying portfolio, where sufficient data are available.

Data Quality

One of the most significant challenges the Company faces in life segment is the quality of provided input data. In 2021, the Company focused to enhance data quality of information stored in its data warehouse covering all the life portfolio data. As this is one of the key challenges faced in the life business, the Company plans to further improve the quality through precisely tracking the portfolio development on the level of underlying insurance policy.

D.2.2.3 Level of Uncertainty Associated with the Value of Technical Provisions

The methods and models used for technical provisions calculations are compliant with the SII requirements. The technical provisions as such are considered to be adequate and reliable. Several limitations and uncertainties present in the value of technical provisions have been identified mainly due to still relatively short market presence of VIG Re and overall quality of data received by clients. The estimated impact on results was assessed by an independent validation. Due to immateriality of the life business and proved profitability this is not deemed to be a significant risk for the Company.

Independent validation of best estimate liabilities calculation has identified main areas of uncertainty associated with the value of technical provisions for life segment as a result of sensitivity analysis. For each driver the isolated effect of assumption changes whereas all other model inputs set at their original best estimate value and without any adjustments of individual valuation mortality and critical illness rates is presented in the tables below.

Table 29 - Main Drivers for Decrease in Gross BEL 2021 (in EUR '000)

Assumption change	Impact on Gross BEL
10% increase in premium based scaling factor	- 3 942
50% relative increase in lapse rates, to a limit of 3% absolute shift up	- 1 439

Table 30 - Main Drivers for Increase in gross BEL 2021 (in EUR '000)

Assumption change	Impact on Gross BEL
SLT riders experience ratio 10% relative shift up	+ 11 304
Mortality experience ratio 10% relative shift up	+ 6 962
50% relative decrease in lapse rates (max 3% absolute shift down)	+ 6 272
10% decrease in premium based scaling factor	+ 3 942
10% increase in expenses	+ 810
NSLT riders experience ratio 5% relative shift up	+ 94

D.2.2.4 Solvency II and IFRS Valuation Differences of Life Technical Provisions

The technical provisions of life business are presented above in D.2.2. The main differences between Solvency II and IFRS liabilities arise from:

- the Solvency II calculation uses best estimate assumptions while the IFRS assumptions include margins for adverse deviation,
- the Solvency II discount rate is specified by regulation (risk free rates provided by EIOPA) while for IFRS the discount rate is given contractually,
- Solvency II provisions include risk margin,
- Differences in the scope of cash-flows between Solvency II and IFRS.

There are no additional specific differences between bases, methods and main assumptions between Solvency II and IFRS liabilities at the level of individual significant types of reinsurance.

D.3 Other Liabilities

As of 31 December 2021, the Company held the following liabilities:

Table 31 - Liabilities Comparison (in EUR '000)

	Solvency II Value		IFRS Value	
	2021	2020	2021	2020
Technical provisions – Non-Life	817 952	485 682	943 240	603 979
Technical provisions – Life (excluding index-linked and unit-linked)	67 886	82 025	88 494	87 202
Technical provisions – index-linked and unit-linked	10 410	8 993	8 480	6 801
Deposits from reinsurers	1 132	9 506	1 052	9 351
Deferred tax liabilities	3 573	9 723	522	1 448
Debts owed to credit institutions	1	0	1	0
Financial liabilities other than debts owed to credit institutions	14 877	4 453	14 877	4 453
Insurance & intermediaries payables	161 379	103 842	161 379	103 842
Reinsurance payables	16 387	12 822	16 387	12 822
Payables (trade, not insurance)	7 624	5 911	7 624	5 911
Subordinated liabilities	55 742	35 708	55 742	35 708
Any other liabilities, not elsewhere shown	6	7	6	7
Total Liabilities	1 156 969	758 672	1 297 804	871 523
Excess of Assets over Liabilities	232 458	224 669	179 835	180 831

D.3.1 Deposits from Reinsurers

Amounts provided from reinsurance companies to VIG Re, held for the payment of the (re) insured losses stemming from the passive reinsurance arrangements.

The fair value for Solvency II is represented by the IFRS value. In case that cash flows arising from these liabilities are incorporated in the best estimate calculation, these liabilities are valued at zero. The valuation of deposits from reinsurers related to life portfolio, follow the same principles as defined in chapter D.1.7.

D.3.2 Deferred Tax Liabilities

Similarly to IFRS, deferred taxes are calculated based on temporary differences between Solvency II and valuations of liabilities performed for tax purposes according to the national tax laws. Differences, which will not reverse in future periods are permanent differences do not lead to deferred taxes. Deferred taxes are not discounted and are shown in net value as net deferred tax liabilities in Solvency II balance sheet.

Following the tax law in Czech Republic implemented in 2019, 100% of the temporary difference between Solvency II valuation and valuation for tax purposes is eliminated.

D.3.3 Financial Liabilities Other than Debts Owed to Credit Institutions

The fair value approach in IAS 39 for the measurement at initial recognition of financial liabilities is deemed a reasonable approximation of the value in the Solvency II balance sheet. Subsequent measurement changes in own credit standing are not taken into the account in the Solvency II balance sheet.

D.3.4 Insurance & Intermediaries Payables

Amounts due/overdue for payment by the valuation date to ceding insurance undertakings and linked to active reinsurance business, but that are not technical provisions (e.g. commissions due to reinsurance brokers but not yet paid by VIG Re). This position also includes payables from reinsurance accepted.

Payables related to future premiums included in the best estimate valuation of technical provisions, are excluded.

D.3.5 Reinsurance Payables

Amounts payable past due to reinsurers (in particular current accounts) other than deposits linked to retrocession, which are not included in reinsurance recoverables. Includes payables to reinsurers that relate to retro-ceded premiums.

Material long-term payables are revalued to fair value using the expected cashflows (no such payables are currently recognised by VIG Re). In case of short-term payables, the IFRS value is deemed a reasonable proxy for the Solvency II valuation.

D.3.6 Payables (Trade, Not Insurance)

This item includes payables to employees, business partners other than insurance or reinsurance undertakings for their services, or other persons.

The fair value for Solvency II is represented by the IFRS value determined at amortized costs (equals the nominal or repayment value).

D.3.7 Excess of Assets over Liabilities

The difference between assets and liabilities is shown here. This excess represents the value of basic own funds, that subject to respective restrictions, are available to cover the capital requirements. More details are discussed in chapter E.1 dedicated to own funds.

D.4 Alternative Methods for Valuation

Apart from the methods described above, the Company does not make use of any other alternative methods for valuation.

D.5 Any Other Information

The Company does not have any further information on valuation for solvency purposes to be disclosed in the SFCR.

CAPITAL
MANAGEMENT



E.1 Own Funds

The Company's available own funds reflect the ability of the Company to absorb any adverse impact stemming from a change in the Solvency II balance sheet (assets and liabilities valuation) or resulting from a change in its own capital.

Capital management serves to ensure compliance with legal and internal standards for quality and quantity in order to meet the solvency capital requirement and minimum capital requirement.

E.1.1 Objective, Policies and Processes for Managing Own Funds

In relation to capital management, the Company aims to ensure the continued existence of the Company on a going-concern basis. In addition to that, the objective is to maintain an optimal capital structure that allows us to fulfil obligations to primary insurers, continue providing dividends to shareholders and meet the Solvency II requirements.

VIG Re's capital management strives to continuously maintain a sufficient level of own funds to cover the SCR and MCR within the predefined comfort zone. Own funds shall be of a sufficient quality to meet the eligibility requirements in Article 82 of the Delegated Regulation. In order to monitor and analyse the ratio of eligible own funds over SCR and MCR, a risk bearing capacity concept has been implemented. As part of own funds management, the Own Risk and Solvency Assessment process is performed at least annually, or on ad-hoc basis when the risk profile significantly changes. The ORSA process incorporates the business planning which is typically considered over a three-year horizon.

The process of capital management at VIG Re comprises the following steps:

Capital Adequacy Assessment

This step assesses the current situation of capital adequacy which is accomplished within the Risk Bearing Capacity framework ensuring that both internal and regulatory requirements are met. This is achieved by the calculation of own funds and capital requirements on quarterly basis in order to ensure that the regulatory requirements for the solvency position are continuously met and also that the internally defined goals on comfort zone and minimum solvency ratio of 135% are satisfied.

Under an adverse scenario where own funds become insufficient, measures are implemented depending on the situations acknowledged.

Capital Planning

Capital planning constitutes the estimation of future capital situation. VIG Re plans the future development of the underwriting business and investment activities, based on which the projected capital requirement and future available own funds are estimated as part of the ORSA process (forward looking assessment). Throughout the planning process it is considered how developments either in business volumes and business mix or changes in existing risk factors may affect profitability, risks and capital needs. Scenarios of adverse developments and their impact on the capital and solvency requirements are analysed in the ORSA process. Compliance with risk tolerance is also ensured during the planning process.

The outputs of the analysis from the adequacy assessment stage are then combined with business planning targets in order to determine possible capital deficiencies and future capital allocation.

Capital management measures

The results of the aforementioned steps in conjunction with business, investment and risk strategy are taken into consideration in order to determine possible capital management measures. A prudent assessment of capital adequacy and a careful capital planning are important phases when forming an understanding of the actions that maintain a proper balance between capital and risks. In order to implement capital management plan, measures are proposed for approval from the Board of Directors and Supervisory Board.

Despite the adverse loss development due to the natural catastrophe events in Europe, the solvency position remained within the comfort zone as of 31 December 2021.

E.1.2 Own Funds Classified by Tiers

The Company's own funds are made up of the ordinary share capital, share premium, reconciliation reserve and subordinated liabilities.

Within the reconciliation reserve, the foreseeable dividend payments from profit are taken into account. It is worth noting that dividends are based on the dividend policy, which defines 85% distribution of profit after tax. This dividend policy is also applied on projected results.

Following the recommendations of EIOPA and CNB in connection with COVID 19, and in view of the financial stability and the solvency situation of VIG Re, the intention of dividend distribution was communicated to CNB and the payment of the dividend was made in December 2021.

The Company's own funds include a subordinated loan of EUR 35 million by VIG Re from VIENNA INSURANCE GROUP AG Wiener Versicherung Gruppe which was issued in June 2018.

As part of the capital planning supporting the strategy, the Company issued a perpetual and subordinated certificate of EUR 20 million, initially subscribed by VIENNA INSURANCE GROUP AG Wiener Versicherung Gruppe.

The development of VIG Re's IFRS equity is presented below:

Table 32 - IFRS Equity (in EUR '000)

IFRS equity	2021	2020
Ordinary share capital	126 850	126 850
Share premium	49	49
Retained earnings	49 950	43 068
Available for sale reserve	2 986	10 864
Total shareholders' equity	179 836	180 831

The following table provides a breakdown of the Solvency II own funds and the reconciliation reserve held by VIG Re as of 31 December 2021 and 31 December 2020 respectively.

Table 33 - Solvency II Own Funds (in EUR '000)

Solvency II Own Funds	2021	2020
Excess of assets over liabilities	232 458	224 669
Foreseeable dividends	17 965	14 254
Ordinary share capital	126 850	126 850
Share capital	49	49
Reconciliation reserve	87 593	83 515
Subordinated liabilities	55 742	35 708
Solvency II Own funds	270 234	246 122

The increase in subordinated liabilities stems from the certificate issued in 2021 as mentioned above.

Foreseeable dividends are subject to final approval by the General Meeting and the Company's basic own funds are distributed to tiers as presented in the following table:

Table 34 - Own funds by tiers 2021 (in EUR '000)

2021	Total	Tier 1 unrestricted	Tier 1 restricted	Tier 2	Tier 3
Ordinary share capital	126 850	126 850	0	0	0
Share premiums	49	49	0	0	0
Reconciliation reserve	87 593	87 593	0	0	0
Subordinated liabilities	55 742	0	20 000	35 742	0
Total basic own funds	270 234	214 492	20 000	35 742	0

For the sake of completeness, the Company's own funds by tiers as of 31 December 2020 are presented in the following table:

Table 35 - Own funds by tiers 2020 (in EUR '000)

2020	Total	Tier 1 unrestricted	Tier 1 restricted	Tier 2	Tier 3
Ordinary share capital	126 850	126 850	0	0	0
Share premiums	49	49	0	0	0
Reconciliation reserve	83 515	83 515	0	0	0
Subordinated liabilities	35 708	0	0	35 708	0
Total basic own funds	246 122	210 414	0	35 708	0

The Company's eligible own funds for SCR and MCR are presented below:

Table 36 - Eligible own funds 2021 (in EUR '000)

2021	Total	Tier 1 unrestricted	Tier 1 restricted	Tier 2	Tier 3
Total eligible to meet SCR	270 234	214 492	20 000	35 742	0
Total eligible to meet MCR	248 513	214 492	20 000	14 020	0

Table 37 - Eligible own funds 2020 (in EUR '000)

2020	Total	Tier 1 unrestricted	Tier 1 restricted	Tier 2	Tier 3
Total eligible to meet SCR	246 122	210 414	0	35 708	0
Total eligible to meet MCR	221 677	210 414	0	11 262	0

Tier 1 unrestricted own funds slightly grew in 2021 as a result of the Company's business activities. Restricted tier 1 own funds include the perpetual and subordinated certificate issued in 2021 while the tier 2 own funds include the subordinated loan which was issued in 2018.


E.2 Solvency Capital Requirement and Minimum Capital Requirement

E.2.1 Amount of the Solvency Capital Requirement and Minimum Capital Requirement

The SCR of the Company as of 31 December 2021 is EUR 155.8 million (2020: EUR 125.1 million). The MCR of the Company as of 31 December 2021 is EUR 70.1 million (2020: EUR 56.3 million).

Figure 9 - Composition of the Solvency Capital Requirement 2021

in EUR million



E.2.2 Solvency Capital Requirement Split by Risk Module

The final solvency capital requirement of the Company is result of the aggregation of the market, counterparty, life underwriting, non-life and health underwriting risks, less a benefit for diversification, loss absorbing capacity of deferred taxes and including an additional risk charge for operational risk.

As commented in chapter C, the SCR is temporarily affected by the 2021 nat cat events mainly in counterparty default risk and operational risk. The SCR for these modules is expected to decrease in the course of 2022. Non-life underwriting is increased due to the Company's increased retention in major retrocession programs.

Table 38 - Solvency Capital Requirement (in EUR '000)

	2021	2020
Market risk	41 339	32 697
Counterparty default risk	36 528	28 196
Life underwriting risk	23 002	24 374
Non-Life underwriting risk	83 588	71 989
Health underwriting risk	16 912	16 705
Intangible asset risk	0	0
Diversification	-66 722	-59 761
Basic solvency capital requirement	134 646	114 200
Operational risk	23 908	17 572
Loss-absorbing capacity of technical provisions	0	0
Loss-absorbing capacity of deferred taxes	-2 782	-6 638
Solvency capital requirement	155 773	125 133

E.2.3 Use of Simplification in Calculations of Sub-Modules, Use of Underwriting Specific Parameters

The Company used one simplification in the applying the standard formula, applied in the calculation of the risk mitigating effects of the retrocession contracts for the counterparty default risk calculation according to Article 107, Delegated Acts 2015/35.

E.2.4 Inputs Used to Calculate the Minimum Capital Requirement

The input used to calculate the MCR of the Company can be found in the table below. The underlying input data (net best estimates and net written premium) are also presented QRT S.28.01.

Table 39 - MCR inputs 2021 (in EUR '000)

SII Line of Business	Net best estimate	Net written premiums
Medical expense insurance and proportional reinsurance	4 264	5 265
Income protection insurance and proportional reinsurance	17 790	5 573
Workers' compensation insurance and proportional reinsurance	66	35
Motor vehicle liability insurance and proportional reinsurance	40 923	27 114
Other motor insurance and proportional reinsurance	6 296	17 627
Marine, aviation and transport insurance and proportional reinsurance	4 403	5 373
Fire and other damage to property insurance and proportional reinsurance	77 480	151 735
General liability insurance and proportional reinsurance	20 463	9 082
Credit and suretyship insurance and proportional reinsurance	310	285
Legal expenses insurance and proportional reinsurance	64	78
Assistance and proportional reinsurance	0	0
Miscellaneous financial loss insurance and proportional reinsurance	10	17
Non-proportional health reinsurance	0	21 096
Non-proportional casualty reinsurance	123 613	44 609
Non-proportional marine, aviation and transport reinsurance	2 655	4 453
Non-proportional property reinsurance	20 905	93 789
Total	319 243	386 132

The MCR increased in 2021 to EUR 70.1 million (2020: EUR 56.3 million) resulting from increased SCR in 2021 via the MCR cap.

Table 40 - Minimum Capital Requirement (in EUR '000)

	2021	2020
Linear MCR	95 322	84 862
SCR	155 773	125 133
MCR cap	70 098	56 310
MCR floor	38 943	31 283
Combined MCR	70 098	56 310
Absolute floor of the MCR	3 600	3 600
Minimum Capital Requirement	70 098	56 310

E.3 Use of the Duration-Based Equity Risk Sub-Module in the Calculation of the Solvency Capital Requirement

The Company did not use the duration-based equity risk sub-module in the calculation of the SCR as of 31 December 2021.

E.4 Differences between the Standard Formula and Any Internal Model Used

The Company has continuously been developing its partial internal model (PIM) since 2015 and gained its approval in 2019. The model is part of the VIG Group PIM; however, subject to many reinsurance specific adjustments.

The model has been developed internally by the Actuarial Services and Retrocession Department with support of VIG Enterprise Risk Management and Arithmetica Consulting GmbH. The main motivation for development of the partial internal model was to more properly reflect the Company’s risk profile in the context of specifics arising from an additional element of complexity due to the reinsurance structure. The intention of the Company was also to develop a model which can be used as a powerful tool to support various management decisions.

The following graph presents all SCR sub-modules. The modules highlighted in green are calculated by making use of the partial internal model:



The application, structure and methodology of the model and its integration are described in the chapters below.

The model covers all material underwriting risks in non-life and in health underwriting business and in addition to the SCR calculation also it is also used in other areas such as:

- planning process,
- reinsurance pricing,
- accumulation control for natural catastrophe and
- retrocession optimization.

The calculated solvency capital requirement corresponds to the value-at-risk for a change in own funds with a confidence level of 99.5% over a period of one year.

The model parametrisation is performed on two different granularity levels. The reserve risk is parametrised on individual reserving segment level, whilst the parametrisation of the premium and catastrophe risk is performed on individual active reinsurance contract level where both attritional and large claims are also randomly simulated. The parametrisation of the premium and catastrophe risk is performed already during the renewal process when each individual contract is quoted and for each contract an actuarial stochastic model is run. After the renewal period all the individual stochastic models are aggregated into a large one where also retrocession structure is set.

The Company's historical accounting data is used for the parametrisation of the reserve risk, for each homogenous reserving group the claims provision best estimates and their standard deviations on one-year horizon are estimated. To reflect the specifics of each active reinsurance contract individual renewal data provided by each client is used wherever possible for parametrisation of the premium and catastrophe risks. Where this data is not sufficient, individual market data is used.

The model allows for a one-year modelling of the underwriting result in the non-life insurance business by making use of a Monte Carlo simulation. In this simulation, a multitude of possible scenarios is generated based on a random number generator. A possible realisation of profit and loss items is estimated (premiums, losses, etc.) for each scenario on gross and net of reinsurance level. Overall, the generated scenarios allow for the identification of risk drivers and analysis of possible extreme events.

Diversification effects in the model between the sub-modules stem directly from the Monte Carlo method along with the implemented correlation structures that use copulas to take into account all material dependencies that occur in reality. This includes, among other things, the correlation of portfolio performance, losses and reserve levels between the modelled lines of business.

In comparison to the standard formula, the model allows for a better reflection of the Company's risk profile. The individual reserving groups across each individual Solvency II line of business are more homogenous and parametrised on the Company's historical data. Within the premium and catastrophe risk, the Company performs the parametrisation on each active reinsurance contract level and also incorporates all characteristics of that contract into the individual stochastic pricing model. Due to the detailed nature of the model also all characteristics of the complex retrocession programme can be integrated.

Therefore, the model is also used for steering of the Company including underwriting decisions, business planning and retrocession purposes. The adequacy of the data and methods is reviewed annually as part of the comprehensive validation. If necessary, the modelling can be adapted quickly to changes to the risk profile. Detailed information on the validation process and governance system for the PIM is provided in chapter B.3.3.

E.5 Non-Compliance with the Minimum Capital Requirement and Non-Compliance with the Solvency Capital Requirement

The Company has maintained capital exceeded the minimum solvency capital requirement and its solvency capital requirement.

E.6 Any Other Information

The Company does not have any further information regarding the capital management to be disclosed in this chapter.

Abbreviations

Abbreviation	Detail
BELs	Best estimates of liabilities
BoD	Board of Directors
BF	Bornhuetter Fergusson Method
CEE	Central and Eastern Europe
DFM	Development Factor Methods
Commission Regulation 2015/35	Commission Delegated Regulation (EU) 2015/35 of 10 October 2014 supplementing Directive 2009/138/EC of the European Parliament and of the Council
Directive 2009/138/EC	Directive 2009/138/EC of the European Parliament and of the Council of 25 November 2009
EIOPA	The European Insurance and Occupational Pensions Authority
EPI	Expected premium income
ERM	Enterprise Risk Management
EUR	Euro
FDB	Future Discretionary Benefits
GDPR	General Data Protection Regulation Regulation (EU) 2016/679 of the European Parliament (General Data Protection Regulation)
SLT health	Similar to Life Techniques
NSLT health	Non-similar to Life Techniques
IASB	The International Accounting Standards Board
IBNER	Incurred but not enough reported
IBNR	Incurred but not reported
ICS	Internal control system
IFRS	International Financial Reporting Standards
IMF	International Monetary Fund
LoB	Line of Business
MCR	Minimum capital requirement
ORSA	Own Risk and Solvency Assessment
P&C	Property & Casualty
QRT	Quantitative Reporting Templates
RBNS	Reported but not Settled
RCM	Risk Control Matrix
ResQ	Loss Reserving System for Insurance and Reinsurance
RSR	The Regular supervisory report
SCR	Solvency capital requirement
SFCR	The Solvency and financial condition report
SII	Solvency II
Solvency II	Refers to Directive 2009/138/EC of the European Parliament and of the Council and related regulation
TP	Technical provision
VaR	Value at Risk

List of Tables


Table 1 - Shareholders of the Undertaking	10
Table 2 - VIG Re Shares 2021	11
Table 3 - VIG Re Shares 2020	11
Table 4 - Income Statement (in '000 EUR)	12
Table 5 - IFRS Results of 2021 (in EUR '000)	14
Table 6 - IFRS Results of 2020 (in EUR '000)	14
Table 7 - Underwriting Result per Segments 2021 (in EUR '000)	14
Table 8 - Underwriting Result per Segments 2020 (in EUR '000)	15
Table 9 - Underwriting Result per Solvency II Line of Business 2021 (in EUR '000)	15
Table 10 - Underwriting Result per Solvency II Line of Business 2020 (in EUR '000)	15
Table 11 - Investments (in EUR '000)	16
Table 12 - Investment Result of Individual Assets Classes 2021 (in EUR '000)	17
Table 13 - Investment Result of Individual Assets Classes 2020 (in EUR '000)	17
Table 14 - Expenses Related to Investment Activity (in EUR '000)	17
Table 15 - Responsibilities of PIM Processes	31
Table 16 - Top 3 Material SCR Risks as of 31 December 2021 (IN EUR '000)	42
Table 17 - Non-Life Underwriting Risk (in EUR '000)	43
Table 18 - Health Underwriting Risk (in EUR '000)	43
Table 19 - Life Underwriting Risk (in EUR '000)	46
Table 20 - Market Risk (in EUR '000)	49
Table 21 - Counterparty Default Risk (in EUR '000)	52
Table 22 - Operational Risk (in EUR '000)	54
Table 23 - Assets Comparison (in EUR '000)	57
Table 24 - Gross Technical Provision (in EUR '000)	61
Table 25 - Sensitivities 2021 (in EUR '000)	65
Table 26 - IFRS and Solvency II Technical Provisions 2021 (in EUR '000)	65
Table 27 - Gross Technical Provisions 2021 (in EUR '000)	67
Table 28 - Gross Technical Provisions 2020 (in EUR '000)	67
Table 29 - Main Drivers for Decrease in Gross BEL 2021 (in EUR '000)	69
Table 30 - Main Drivers for Increase in Gross BEL 2021 (in EUR '000)	69
Table 31 - Liabilities Comparison (in EUR '000)	70
Table 32 - IFRS Equity (in EUR '000)	74
Table 33 - Solvency II Own Funds (in EUR '000)	75
Table 34 - Own funds by tiers 2021 (in EUR '000)	75
Table 35 - Own funds by tiers 2020 (in EUR '000)	75
Table 36 - Eligible Own Funds 2021 (in EUR '000)	75
Table 37 - Eligible Own Funds 2020 (in EUR '000)	76
Table 38 - Solvency Capital Requirement (in EUR '000)	77
Table 39 - MCR Inputs 2021 (in EUR '000)	78
Table 40 - Minimum Capital Requirement (in EUR '000)	78

List of Figures

Figure 1 - Underwriting Territories.....	9
Figure 2 - GWP per Segment in (EUR '000).....	13
Figure 3 - GWP P&C per Line of Business (in EUR '000)	13
Figure 4 - GWP P&C per Country (in EUR '000).....	13
Figure 5 - Statutory Bodies and Organisational Units in the Company.....	28
Figure 6 - ORSA Process.....	33
Figure 7 - Composition of the SCR 2021	41
Figure 8 - Composition of Market SCR 2021	49
Figure 9 - Composition of the Solvency Capital Requirement 2021.....	77
Figure 10 - SCR Components.....	80

Annexes

Annex I – Organisational Structure as of 31 December 2021



Annex II – Quantitative Information

List of reports:

S.02.01.02	Balance sheet
S.05.01.02	Premiums, claims and expenses by line of business
S.05.02.01	Premiums, claims and expenses by country
S.12.01.02	Life and Health SLT Technical Provisions
S.17.01.02	Non-Life Technical Provisions
S.19.01.21	Non-Life Insurance Claims Information
S.22.01.21	Impact of long term guarantees and transitional measures
S.23.01.01	Own funds
S.25.02.21	Solvency Capital Requirement – for undertakings using the Partial Internal Model
S.28.01.01	Minimum Capital Requirement - Only Life or only Non-Life insurance or reinsurance activity
S.28.02.01	Minimum Capital Requirement – Both Life and Non-Life insurance activity

Figures are in thousands EUR unless stated otherwise.

VIG Re's collateral arrangements are well below 60% of total assets. The threshold of 60% is defined in Article 192 (2) of the Solvency II Delegated Regulation (EU) 2015/35 and this information is relevant for the calculation of the counterparty default risk with respect to VIG Re using Solvency II standard formula.

Assets		Solvency II value C0010
Intangible assets	R0030	
Deferred tax assets	R0040	
Pension benefit surplus	R0050	
Property, plant & equipment held for own use	R0060	2 548
Investments (other than assets held for index-linked and unit-linked contracts)	R0070	501 116
Property (other than for own use)	R0080	
Holdings in related undertakings, including participations	R0090	8 663
Equities	R0100	1 173
Equities - listed	R0110	0
Equities - unlisted	R0120	1 173
Bonds	R0130	351 177
Government Bonds	R0140	206 390
Corporate Bonds	R0150	144 787
Structured notes	R0160	
Collateralised securities	R0170	
Collective Investments Undertakings	R0180	140 102
Derivatives	R0190	
Deposits other than cash equivalents	R0200	0
Other investments	R0210	
Assets held for index-linked and unit-linked contracts	R0220	8 480
Loans and mortgages	R0230	12 374
Loans on policies	R0240	
Loans and mortgages to individuals	R0250	
Other loans and mortgages	R0260	12 374
Reinsurance recoverables from:	R0270	476 474
Non-life and health similar to non-life	R0280	472 058
Non-life excluding health	R0290	452 437
Health similar to non-life	R0300	19 622
Life and health similar to life, excluding health and index-linked and unit-linked	R0310	4 416
Health similar to life	R0320	
Life excluding health and index-linked and unit-linked	R0330	4 416
Life index-linked and unit-linked	R0340	0
Deposits to cedants	R0350	105 828
Insurance and intermediaries receivables	R0360	109 837
Reinsurance receivables	R0370	104 990
Receivables (trade, not insurance)	R0380	6 672
Own shares (held directly)	R0390	0
Amounts due in respect of own fund items or initial fund called up but not yet paid in	R0400	
Cash and cash equivalents	R0410	60 754
Any other assets, not elsewhere shown	R0420	353
Total assets	R0500	1 389 427

Liabilities		Solvency II value C0010
Technical provisions – non-life	R0510	817 952
Technical provisions – non-life (excluding health)	R0520	775 752
TP calculated as a whole	R0530	0
Best Estimate	R0540	749 559
Risk margin	R0550	26 192
Technical provisions - health (similar to non-life)	R0560	42 200
TP calculated as a whole	R0570	0
Best Estimate	R0580	39 112
Risk margin	R0590	3 088
Technical provisions - life (excluding index-linked and unit-linked)	R0600	67 886
Technical provisions - health (similar to life)	R0610	-711
TP calculated as a whole	R0620	0
Best Estimate	R0630	-2 163
Risk margin	R0640	1 452
Technical provisions – life (excluding health and index-linked and unit-linked)	R0650	68 598
TP calculated as a whole	R0660	0
Best Estimate	R0670	57 335
Risk margin	R0680	11 263
Technical provisions – index-linked and unit-linked	R0690	10 410
TP calculated as a whole	R0700	0
Best Estimate	R0710	8 782
Risk margin	R0720	1 628
Contingent liabilities	R0740	
Provisions other than technical provisions	R0750	
Pension benefit obligations	R0760	
Deposits from reinsurers	R0770	1 132
Deferred tax liabilities	R0780	3 573
Derivatives	R0790	
Debts owed to credit institutions	R0800	1
Financial liabilities other than debts owed to credit institutions	R0810	14 877
Insurance & intermediaries payables	R0820	161 379
Reinsurance payables	R0830	16 387
Payables (trade, not insurance)	R0840	7 624
Subordinated liabilities	R0850	55 742
Subordinated liabilities not in BOF	R0860	
Subordinated liabilities in BOF	R0870	55 742
Any other liabilities, not elsewhere shown	R0880	6
Total liabilities	R0900	1 156 969
Excess of assets over liabilities	R1000	232 458

Annex II - S.05.01.02

Premiums, claims and expenses by line of business

	Line of Business for: non-life insurance and reinsurance obligations (direct business and accepted proportional reinsurance)									
	Medical expense insurance	Income protection insurance	Workers' compensation insurance	Motor vehicle liability insurance	Other motor insurance	Marine, aviation and transport insurance	Fire and other damage to property insurance	General liability insurance	Credit and suretyship insurance	
	C0010	C0020	C0030	C0040	C0050	C0060	C0070	C0080	C0090	
Premiums written										
Gross - Direct Business	R0110									
Gross - Proportional reinsurance accepted	R0120	7 535	5 610	36	36 176	18 795	9 559	242 443	9 740	1 398
Gross - Non-proportional reinsurance accepted	R0130									
Reinsurers' share	R0140	2 269	36		9 062	1 168	4 186	90 708	659	1 113
Net	R0200	5 265	5 573	35	27 114	17 627	5 373	151 735	9 082	285
Premiums earned										
Gross - Direct Business	R0210									
Gross - Proportional reinsurance accepted	R0220	7 858	5 545	36	36 280	18 717	9 243	236 473	9 646	1 218
Gross - Non-proportional reinsurance accepted	R0230									
Reinsurers' share	R0240	2 353	38		10 118	1 141	4 123	89 432	632	1 021
Net	R0300	5 504	5 507	35	26 162	17 575	5 120	147 041	9 014	197
Claims incurred										
Gross - Direct Business	R0310									
Gross - Proportional reinsurance accepted	R0320	4 366	5 374	33	28 577	10 146	5 905	198 890	6 068	240
Gross - Non-proportional reinsurance accepted	R0330									
Reinsurers' share	R0340	1 322	-196	-1	11 062	785	1 697	79 431	364	157
Net	R0400	3 044	5 570	33	17 514	9 361	4 208	119 459	5 705	83
Changes in other technical provisions										
Gross - Direct Business	R0410									
Gross - Proportional reinsurance accepted	R0420	0	250	0	0	0	0	0	0	0
Gross - Non- proportional reinsurance accepted	R0430									
Reinsurers'share	R0440									
Net	R0500	0	250	0	0	0	0	0	0	0
Expenses incurred	R0550	-50		0	368	391	1 085	24 477	192	378
Other expenses	R1200									
Total expenses	R1300									

Annex II - S.05.01.02

Premiums, claims and expenses by line of business

		Line of Business for: non-life insurance and reinsurance obligations (direct business and accepted proportional reinsurance)			Line of business for: accepted non-proportional reinsurance				Total
		Legal expenses insurance	Assistance	Miscellaneous financial loss	Health	Casualty	Marine, aviation, transport	Property	
		C0100	C0110	C0120	C0130	C0140	C0150	C0160	
Premiums written									
Gross - Direct Business	R0110								
Gross - Proportional reinsurance accepted	R0120	78	0	18					331 389
Gross - Non-proportional reinsurance accepted	R0130				26 291	66 407	9 130	195 191	297 020
Reinsurers' share	R0140	1	0	1	5 195	21 798	4 678	101 402	242 277
Net	R0200	78	0	17	21 096	44 609	4 453	93 789	386 132
Premiums earned									
Gross - Direct Business	R0210								
Gross - Proportional reinsurance accepted	R0220	78	0	18					325 111
Gross - Non-proportional reinsurance accepted	R0230				26 441	64 161	9 287	200 500	300 390
Reinsurers' share	R0240		0		5 332	20 952	4 737	105 440	245 320
Net	R0300	78	0	18	21 109	43 209	4 550	95 061	380 181
Claims incurred									
Gross - Direct Business	R0310								
Gross - Proportional reinsurance accepted	R0320	51	0	3					259 651
Gross - Non-proportional reinsurance accepted	R0330				10 710	37 384	4 560	440 437	493 090
Reinsurers' share	R0340		0	0	6 622	4 431	1 908	357 925	465 505
Net	R0400	52	0	3	4 088	32 953	2 653	82 512	287 237
Changes in other technical provisions									
Gross - Direct Business	R0410								
Gross - Proportional reinsurance accepted	R0420	0	0	0					250
Gross - Non- proportional reinsurance accepted	R0430				0	0	0	0	0
Reinsurers'share	R0440								
Net	R0500	0	0	0	0	0	0	0	250
Expenses incurred	R0550	0	0	0	-906	-2 912	-500	337	22 860
Other expenses	R1200								78 379
Total expenses	R1300								101 239

Annex II - S.05.01.02

Premiums, claims and expenses by line of business

	Line of Business for: life insurance obligations						Life reinsurance obligations		Total
	Health insurance	Insurance with profit participation	Index-linked and unit-linked insurance	Other life insurance	Annuities stemming from non-life insurance contracts and relating to health insurance obligations	Annuities stemming from non-life insurance contracts and relating to insurance obligations other than health insurance obligations	Health reinsurance	Life reinsurance	
	C0210	C0220	C0230	C0240	C0250	C0260	C0270	C0280	C0300
Premiums written									
Gross	R1410						1 249	31 618	32 867
Reinsurers' share	R1420						0	8 494	8 494
Net	R1500						1 249	23 124	24 373
Premiums earned									
Gross	R1510						1 249	31 167	32 416
Reinsurers' share	R1520						0	8 400	8 400
Net	R1600						1 249	22 767	24 016
Claims incurred									
Gross	R1610						102	16 733	16 834
Reinsurers' share	R1620						0	2 682	2 682
Net	R1700						102	14 050	14 152
Changes in other technical provisions									
Gross	R1710						-862	1 230	368
Reinsurers' share	R1720						0	-122	-122
Net	R1800						-862	1 352	490
Expenses incurred	R1900						658	6 579	7 238
Other expenses	R2500								
Total expenses	R2600								7 238

Annex II - S.05.01.02

Premiums, claims and expenses by country

	Home Country	Top 5 countries (by amount of gross premiums written) - non-life obligations					Total Top 5 and home country
	C0010	C0020	C0030	C0040	C0050	C0060	C0070
	R0010	AT	DE	IT	PL	TR	
	C0080	C0090	C0100	C0110	C0120	C0130	C0140
Premiums written							
Gross - Direct Business	R0110						
Gross - Proportional reinsurance accepted	R0120	14 833	95 475	40 059	25 111	18 531	217 155
Gross - Non-proportional reinsurance accepted	R0130	37 990	99 777	24 715	11 898	15 861	199 879
Reinsurers' share	R0140	38 157	85 896	11 646	2 080	17 716	169 854
Net	R0200	14 667	109 356	53 129	34 929	16 676	247 180
Premiums earned							
Gross - Direct Business	R0210						
Gross - Proportional reinsurance accepted	R0220	14 756	94 738	39 287	24 895	17 083	214 794
Gross - Non-proportional reinsurance accepted	R0230	38 309	99 578	28 589	12 636	16 015	204 825
Reinsurers' share	R0240	38 314	85 144	13 308	2 667	17 230	172 313
Net	R0300	14 751	109 172	54 568	34 864	15 868	247 306
Claims incurred							
Gross - Direct Business	R0310						
Gross - Proportional reinsurance accepted	R0320	21 600	82 337	35 219	14 919	8 976	184 224
Gross - Non-proportional reinsurance accepted	R0330	46 333	248 361	93 007	14 312	20 281	425 081
Reinsurers' share	R0340	58 583	228 771	85 106	302	17 661	403 691
Net	R0400	9 350	101 927	43 120	28 929	11 596	205 613
Changes in other technical provisions							
Gross - Direct Business	R0410						
Gross - Proportional reinsurance accepted	R0420		0	-250	0	0	-250
Gross - Non- proportional reinsurance accepted	R0430						0
Reinsurers'share	R0440						0
Net	R0500		0	-250	0	0	-250
Expenses incurred	R0550	583	11 104	15 016	11 372	3 640	45 479
Other expenses	R1200						
Total expenses	R1300						45 479

Annex II - S.05.02.01

Premiums, claims and expenses by country

	Home Country	Top 5 countries (by amount of gross premiums written) - life obligations					Total Top 5 and home country	
	C0150	C0160	C0170	C0180	C0190	C0200	C0210	
	R1400	AT	DE	HU	PL	SK		
	C0220	C0230	C0240	C0250	C0260	C0270	C0280	
Premiums written								
Gross	R1410	438	9 075	1 560	6 669	1 566	8 487	27 795
Reinsurers' share	R1420	4	910	0	2 056	263	1 548	4 781
Net	R1500	434	8 165	1 560	4 612	1 303	6 939	23 014
Premiums earned								
Gross	R1510	438	8 969	1 127	6 669	1 526	8 554	27 284
Reinsurers' share	R1520	4	813	0	2 056	263	1 582	4 717
Net	R1600	435	8 156	1 127	4 612	1 263	6 973	22 567
Claims incurred								
Gross	R1610	1	10 300	60	1 127	466	2 640	14 595
Reinsurers' share	R1620	6	-29	0	790	9	1 242	2 018
Net	R1700	-5	10 330	60	337	457	1 397	12 576
Changes in other technical provisions								
Gross	R1710	0	-4 201	936	1 002	0	1 679	-584
Reinsurers' share	R1720	0	0	0	-71	0	0	-71
Net	R1800	0	-4 201	936	1 074	0	1 679	-512
Expenses incurred	R1900	163	1 958	131	2 662	339	2 469	7 723
Other expenses	R2500							
Total expenses	R2600							7 723

		Index-linked and unit-linked insurance				Other life insurance		Annuities stemming from non-life insurance contracts and relating to insurance obligation other than health insurance obligations	Accepted reinsurance	Total (Life other than health insurance, incl. Unit-Linked)
		Insurance with profit participation	Contracts without options and guarantees	Contracts with options or guarantees	Contracts without options and guarantees	Contracts with options or guarantees	C0090			
Technical provisions calculated as a whole	R0010									
Total Recoverables from reinsurance/ SPV and Finite Re after the adjustment for expected losses due to counterparty default associated to TP as a whole	R0020									
Technical provisions calculated as a sum of BE and RM										
Best Estimate										
Gross Best Estimate	R0030								66 117	66 117
Total Recoverables from reinsurance/ SPV and Finite Re after the adjustment for expected losses due to counterparty default	R0080								4 416	4 416
Best estimate minus recoverables from reinsurance/SPV and Finite Re - total	R0090								61 701	61 701
Risk Margin	R0100								12 891	12 891
Amount of the transitional on Technical Provisions										
Technical Provisions calculated as a whole	R0110									
Best estimate	R0120									
Risk margin	R0130									
Technical provisions - total	R0200								79 008	79 008

		Health insurance (direct business)			Annuities stemming from non-life insurance contracts and relating to health insurance obligations	Health reinsurance (reinsurance accepted)	Total (Health similar to life insurance)
		Contracts without options and guarantees	Contracts with options or guarantees				
		C0160	C0170	C0180	C0190	C0200	C0210
Technical provisions calculated as a whole	R0010						
Total Recoverables from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default associated to TP as a whole	R0020						
Technical provisions calculated as a sum of BE and RM							
Best Estimate							
Gross Best Estimate	R0030					-2 163	-2 163
Total Recoverables from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default	R0080					0	0
Best estimate minus recoverables from reinsurance/SPV and Finite Re - total	R0090					-2 163	-2 163
Risk Margin	R0100					1 452	1 452
Amount of the transitional on Technical Provisions							
Technical Provisions calculated as a whole	R0110						
Best estimate	R0120						
Risk margin	R0130						
Technical provisions - total	R0200					-711	-711

		Direct business and accepted proportional reinsurance								
		Medical expense insurance	Income protection insurance	Workers' compensation insurance	Motor vehicle liability insurance	Other motor insurance	Marine, aviation and transport insurance	Fire and other damage to property insurance	General liability insurance	Credit and suretyship insurance
		C0020	C0030	C0040	C0050	C0060	C0070	C0080	C0090	C0100
Technical provisions calculated as a whole	R0010									
Total Recoverables from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default associated to TP as a whole	R0050									
Technical provisions calculated as a sum of BE and RM										
Best estimate										
Premium provisions										
Gross	R0060	-594	372	39	2 654	-185	-42	12 398	497	146
Total recoverable from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default	R0140	-460	-1	0	-735	-50	-75	11 058	42	-117
Net Best Estimate of Premium Provisions	R0150	-134	373	39	3 389	-135	33	1 339	454	263
Claims provisions										
Gross	R0160	4 089	16 905	27	43 076	6 519	6 871	142 960	20 210	696
Total recoverable from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default	R0240	-309	-511	0	5 542	87	2 501	66 819	201	649
Net Best Estimate of Claims Provisions	R0250	4 398	17 416	27	37 534	6 431	4 370	76 141	20 008	47
Total Best estimate - gross	R0260	3 495	17 277	66	45 730	6 333	6 829	155 358	20 706	842
Total Best estimate - net	R0270	4 264	17 790	66	40 923	6 296	4 403	77 480	20 463	310
Risk margin	R0280	109	2 471	5	1 932	238	198	2 707	888	22
Amount of the transitional on Technical Provisions										
Technical Provisions calculated as a whole	R0290									
Best estimate	R0300									
Risk margin	R0310									

	Direct business and accepted proportional reinsurance									
	Medical expense insurance	Income protection insurance	Workers' compensation insurance	Motor vehicle liability insurance	Other motor insurance	Marine, aviation and transport insurance	Fire and other damage to property insurance	General liability insurance	Credit and suretyship insurance	
	C0020	C0030	C0040	C0050	C0060	C0070	C0080	C0090	C0100	
Technical provisions - total										
Technical provisions - total	R0320	3 603	19 748	71	47 662	6 572	7 027	158 065	21 594	865
Recoverable from reinsurance contract/SPV and Finite Re after the adjustment for expected losses due to counterparty default - total	R0330	-769	-512	0	4 807	37	2 427	77 878	244	532
Technical provisions minus recoverables from reinsurance/ SPV and Finite Re - total	R0340	4 372	20 260	71	42 855	6 535	4 601	80 188	21 350	333

		Direct business and accepted proportional reinsurance			Accepted non-proportional reinsurance			Total Non-Life obligation	
		Legal expenses insurance	Assistance	Miscellaneous financial loss	Non-proportional health reinsurance	Non-proportional casualty reinsurance	Non-proportional marine, aviation and transport reinsurance		Non-proportional property reinsurance
		C0110	C0120	C0130	C0140	C0150	C0160		C0170
Technical provisions calculated as a whole	R0010								
Total Recoverables from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default associated to TP as a whole	R0050								
Technical provisions calculated as a sum of BE and RM									
Best estimate									
Premium provisions									
Gross	R0060	-8	0		-12 048	-3 570	-1 889	-41 409	-43 640
Total recoverable from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default	R0140	0	0	0	-1 306	-1 628	-930	-22 072	-16 274
Net Best Estimate of Premium Provisions	R0150	-8	0		-10 742	-1 942	-959	-19 337	-27 366
Claims provisions									
Gross	R0160	73	0	10	30 322	207 414	10 662	342 476	832 311
Total recoverable from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default	R0240	1	0	0	22 209	81 859	7 048	302 234	488 332
Net Best Estimate of Claims Provisions	R0250	72	0	10	8 112	125 555	3 614	40 242	343 979
Total Best estimate - gross	R0260	66	0	10	18 274	203 844	8 773	301 068	788 672
Total Best estimate - net	R0270	64	0	10	-2 629	123 613	2 655	20 905	316 613
Risk margin	R0280	3	0		504	15 718	456	4 031	29 281
Amount of the transitional on Technical Provisions									
Technical Provisions calculated as a whole	R0290								
Best estimate	R0300								
Risk margin	R0310								

		Direct business and accepted proportional reinsurance				Accepted non-proportional reinsurance			Total Non-Life obligation
		Legal expenses insurance	Assistance	Miscellaneous financial loss	Non-proportional health reinsurance	Non-proportional casualty reinsurance	Non-proportional marine, aviation and transport reinsurance	Non-proportional property reinsurance	
		C0110	C0120	C0130	C0140	C0150	C0160	C0170	
Technical provisions - total									
Technical provisions - total	R0320	68	0	10	18 778	219 561	9 229	305 098	817 952
Recoverable from reinsurance contract/SPV and Finite Re after the adjustment for expected losses due to counterparty default - total	R0330	1	0	0	20 903	80 230	6 118	280 163	472 058
Technical provisions minus recoverables from reinsurance/SPV and Finite Re - total	R0340	67	0	10	-2 125	139 331	3 110	24 936	345 894

Annex II - S.19.01.21

Non-life Insurance Claims Information

Total Non-Life Business

Accident year / Underwriting year **Z0010** Underwriting year

Gross Claims Paid (non-cumulative)
(absolute amount)

	Year	Development year											In Current year	Sum of years (cumulative)		
		0	1	2	3	4	5	6	7	8	9	10 & +				
		C0010	C0020	C0030	C0040	C0050	C0060	C0070	C0080	C0090	C0100	C0110			C0170	C0180
Prior	R0100												1 812	R0100	1 812	1 812
N-9	R0160	68 402	30 623	9 894	3 552	2 095	3 163	1 054	1 566	1 720	1 292			R0160	1 292	123 362
N-8	R0170	127 182	63 330	20 545	9 181	3 424	3 046	1 663	864	1 199				R0170	1 199	230 432
N-7	R0180	101 922	51 290	31 124	17 053	11 263	23 109	1 283	931					R0180	931	237 975
N-6	R0190	91 074	57 115	28 775	13 680	9 187	7 507	1 670						R0190	1 670	209 008
N-5	R0200	77 712	48 501	15 283	6 957	5 657	2 393							R0200	2 393	156 503
N-4	R0210	115 710	77 398	33 832	28 536	11 791								R0210	11 791	267 267
N-3	R0220	86 865	57 272	28 553	11 219									R0220	11 219	183 910
N-2	R0230	106 830	88 679	43 101										R0230	43 101	238 611
N-1	R0240	112 507	77 839											R0240	77 839	190 346
N	R0250	258 352												R0250	258 352	258 352
													Total	R0260	411 599	2 097 578

Annex II - S.19.01.21

Non-life Insurance Claims Information

Gross undiscounted Best Estimate Claims Provisions
(absolute amount)

	Year	Development year										Year end (discounted data)			
		0	1	2	3	4	5	6	7	8	9	10 & +			
		C0200	C0210	C0220	C0230	C0240	C0250	C0260	C0270	C0280	C0290	C0300	C0360		
Prior	R0100											39 796	R0100	36 788	
N-9	R0160	0	0	0	0	21 141	17 726	17 851	16 121	12 867	12 424		R0160	11 207	
N-8	R0170	0	0	0	25 831	23 984	16 422	14 477	12 597	12 197			R0170	11 019	
N-7	R0180	0	0	53 183	61 413	49 947	18 358	13 624	14 780				R0180	13 144	
N-6	R0190	0	82 976	67 489	49 581	30 094	24 491	23 293					R0190	19 776	
N-5	R0200	89 889	61 459	44 135	29 521	31 425	31 864						R0200	26 851	
N-4	R0210	142 139	108 345	70 599	49 893	41 957							R0210	38 014	
N-3	R0220	101 617	82 393	42 440	40 598								R0220	36 120	
N-2	R0230	176 713	121 155	76 256									R0230	67 854	
N-1	R0240	184 424	141 541										R0240	131 940	
N	R0250	451 483											R0250	439 599	
													Total	R0260	832 311

	Amount with Long Term Guarantee measures and transitionals	Impact of transitional on technical provisions	Impact of transitional on interest rate	Impact of volatility adjustment set to zero	Impact of matching adjustment set to zero
	C0010	C0030	C0050	C0070	C0090
Technical provisions	R0010				
Basic own funds	R0020				
Eligible own funds to meet Solvency Capital Requirement	R0050				
Solvency Capital Requirement	R0090				
Eligible own funds to meet Minimum Capital Requirement	R0100				
Minimum Capital Requirement	R0110				

Annex II - S.23.01.01

Own funds

		Total	Tier 1 - unrestricted	Tier 1 - restricted	Tier 2	Tier 3
		C0010	C0020	C0030	C0040	C0050
Basic own funds before deduction for participations in other financial sector as foreseen in article 68 of Delegated Regulation (EU) 2015/35						
Ordinary share capital (gross of own shares)	R0010	126 850	126 850			
Share premium account related to ordinary share capital	R0030	50	50			
initial funds, members' contributions or the equivalent basic own - fund item for mutual and mutual-type undertakings	R0040	0	0			
Subordinated mutual member accounts	R0050					
Surplus funds	R0070					
Preference shares	R0090					
Share premium account related to preference shares	R0110					
Reconciliation reserve	R0130	87 593	87 593			
Subordinated liabilities	R0140	55 742		20 000	35 742	
An amount equal to the value of net deferred tax assets	R0160					
Other own fund items approved by the supervisory authority as basic own funds not specified above	R0180					
Own funds from the financial statements that should not be represented by the reconciliation reserve and do not meet the criteria to be classified as Solvency II own funds						
Own funds from the financial statements that should not be represented by the reconciliation reserve and do not meet the criteria to be classified as Solvency II own funds	R0220					
Deductions						
Deductions for participations in financial and credit institutions	R0230					
Total basic own funds after deductions	R0290	270 235	214 493	20 000	35 742	
Ancillary own funds						
Unpaid and uncalled ordinary share capital callable on demand	R0300					
Unpaid and uncalled initial funds, members' contributions or the equivalent basic own fund item for mutual and mutual - type undertakings, callable on demand	R0310					
Unpaid and uncalled preference shares callable on demand	R0320					
A legally binding commitment to subscribe and pay for subordinated liabilities on demand	R0330					
Letters of credit and guarantees under Article 96(2) of the Directive 2009/138/EC	R0340					
Letters of credit and guarantees other than under Article 96(2) of the Directive 2009/138/EC	R0350					
Supplementary members calls under first subparagraph of Article 96(3) of the Directive 2009/138/EC	R0360					
Supplementary members calls - other than under first subparagraph of Article 96(3) of the Directive 2009/138/EC	R0370					
Other ancillary own funds	R0390					
Total ancillary own funds	R0400					

Annex II - S.23.01.01

Own funds

		Total	Tier 1 - unrestricted	Tier 1 - restricted	Tier 2	Tier 3
		C0010	C0020	C0030	C0040	C0050
Available and eligible own funds						
Total available own funds to meet the SCR	R0500	270 235	214 493	20 000	35 742	
Total available own funds to meet the MCR	R0510	270 235	214 493	20 000	35 742	
Total eligible own funds to meet the SCR	R0540	270 235	214 493	20 000	35 742	0
Total eligible own funds to meet the MCR	R0550	248 513	214 493	20 000	14 020	
SCR	R0580	155 773				
MCR	R0600	70 098				
Ratio of Eligible own funds to SCR	R0620	173,48%				
Ratio of Eligible own funds to MCR	R0640	354,52%				
C0060						
Reconciliation reserve						
Excess of assets over liabilities	R0700	232 458				
Own shares (held directly and indirectly)	R0710	0				
Foreseeable dividends, distributions and charges	R0720	17 965				
Other basic own fund items	R0730	126 900				
Adjustment for restricted own fund items in respect of matching adjustment portfolios and ring fenced funds	R0740	0				
Reconciliation reserve	R0760	87 593				
Expected profits						
Expected profits included in future premiums (EPIFP) - Life business	R0770	22 448				
Expected profits included in future premiums (EPIFP) - Non- life business	R0780	64 068				
Total Expected profits included in future premiums (EPIFP)	R0790	86 516				

	Gross solvency capital requirement	USP Simplifications	
		C0110	C0090 C0100
Market risk	R0010		
Counterparty default risk	R0020		
Life underwriting risk	R0030		
Health underwriting risk	R0040		
Non-life underwriting risk	R0050		
Diversification	R0060		
Intangible asset risk	R0070		
Basic Solvency Capital Requirement	R0100		
Calculation of Solvency Capital Requirement		C0100	
Operational risk	R0130		
Loss-absorbing capacity of technical provisions	R0140		
Loss-absorbing capacity of deferred taxes	R0150		
Capital requirement for business operated in accordance with Art. 4 of Directive 2003/41/EC	R0160		
Solvency capital requirement excluding capital add-on	R0200		
Capital add-on already set	R0210		
Solvency capital requirement	R0220		
Other information on SCR			
Capital requirement for duration-based equity risk sub-module	R0400		
Total amount of Notional Solvency Capital Requirement for remaining part	R0410		
Total amount of Notional Solvency Capital Requirements for ring fenced funds	R0420		
Total amount of Notional Solvency Capital Requirement for matching adjustment portfolios	R0430		
Diversification effects due to RFF nSCR aggregation for article 304	R0440		
		Yes/No	
		C0109	
Approach based on average tax rate	R0590		
		LAC DT	
Calculation of loss absorbing capacity of deferred taxes		C0130	
LAC DT	R0640		
LAC DT justified by reversion of deferred tax liabilities	R0650		
LAC DT justified by reference to probable future taxable economic profit	R0660		
LAC DT justified by carry back, current year	R0670		
LAC DT justified by carry back, future years	R0680		
Maximum LAC DT	R0690		

Annex II - S.25.02.21 Solvency Capital Requirement - for undertakings using the standard formula and partial internal model

Unique number of component	Components description	Calculation of the Solvency Capital Requirement	Amount modelled	USP	Simplifications
C0010	C0020	C0030	C0070	C0090	C0120
1	Market risk	41 339	0		
2	Counterparty default risk	36 528	0		
3	Life underwriting risk	23 002	0		
4	Health underwriting risk	16 912	12 884		
5	Non-life underwriting risk	83 588	83 588		
6	Intangible asset risk	0	0		
7	Operational risk	23 908	0		
8	LAC Technical Provisions (negative amount)	0	0		
9	LAC Deferred Taxes (negative amount)	-2 782	0		
Calculation of Solvency Capital Requirement		C0100			
Total undiversified components	R0110	222 495			
Diversification	R0060	-66 722			
Capital requirement for business operated in accordance with Art. 4 of Directive 2003/41/EC	R0160	0			
Solvency capital requirement excluding capital add-on	R0200	155 773			
Capital add-ons already set	R0210	0			
Solvency capital requirement	R0220	155 773			
Other information on SCR					
Amount/estimate of the overall loss-absorbing capacity of technical provisions	R0300				
Amount/estimate of the overall loss-absorbing capacity of deferred taxes	R0310	-2 782			
Capital requirement for duration-based equity risk sub-module	R0400	0			
Total amount of Notional Solvency Capital Requirements for remaining part	R0410	0			
Total amount of Notional Solvency Capital Requirements for ring fenced funds (other than those related to business operated in accordance with Art. 4 of Directive 2003/41/EC (transitional))	R0420	0			
Total amount of Notional Solvency Capital Requirement for matching adjustment portfolios	R0430	0			
Diversification effects due to RFF nSCR aggregation for article 304	R0440	0			
				Yes/No	
				C0109	
Approach based on average tax rate	R0590			Yes	
				LAC DT	
Calculation of loss absorbing capacity of deferred taxes		C0130			
LAC DT	R0640	-2 782			
LAC DT justified by reversion of deferred tax liabilities	R0650	-2 782			
LAC DT justified by reference to probable future taxable economic profit	R0660	0			
LAC DT justified by carry back, current year	R0670	0			
LAC DT justified by carry back, future years	R0680	0			
Maximum LAC DT	R0690	-2 782			

Annex II - S.28.01.01
Minimum Capital Requirement - Only life or only non-life insurance or reinsurance activity
Linear formula component for non-life insurance and reinsurance obligations

		C0010
MCRNL Result	R0010	87 795

		Net (of reinsurance/ SPV) best estimate and TP calculated as a whole	Net (of reinsurance) written premiums in the last 12 months
		C0020	C0030
Medical expense insurance and proportional reinsurance	R0020	4 264	5 265
Income protection insurance and proportional reinsurance	R0030	17 790	5 573
Workers' compensation insurance and proportional reinsurance	R0040	66	35
Motor vehicle liability insurance and proportional reinsurance	R0050	40 923	27 114
Other motor insurance and proportional reinsurance	R0060	6 296	17 627
Marine, aviation and transport insurance and proportional reinsurance	R0070	4 403	5 373
Fire and other damage to property insurance and proportional reinsurance	R0080	77 480	151 735
General liability insurance and proportional reinsurance	R0090	20 463	9 082
Credit and suretyship insurance and proportional reinsurance	R0100	310	285
Legal expenses insurance and proportional reinsurance	R0110	64	78
Assistance and proportional reinsurance	R0120	0	0
Miscellaneous financial loss insurance and proportional reinsurance	R0130	10	17
Non-proportional health reinsurance	R0140	0	21 096
Non-proportional casualty reinsurance	R0150	123 613	44 609
Non-proportional marine, aviation and transport reinsurance	R0160	2 655	4 453
Non-proportional property reinsurance	R0170	20 905	93 789

Annex II - S.28.01.01

Minimum Capital Requirement - Only life or only non-life insurance or reinsurance activity

Linear formula component for life insurance and reinsurance obligations

		C0040
MCRL Result	R0200	7 527

		Net (of reinsurance/ SPV) best estimate and TP calculated as a whole	Net (of reinsurance/ SPV) total capital at risk
		C0050	C0060
Obligations with profit participation - guaranteed benefits	R0210	54 958	
Obligations with profit participation - future discretionary benefits	R0220		
Index-linked and unit-linked insurance obligations	R0230	8 782	
Other life (re)insurance and health (re)insurance obligations	R0240	0	
Total capital at risk for all life (re)insurance obligations	R0250		7 759 956

Overall MCR calculation

		C0070
Linear MCR	R0300	95 322
SCR	R0310	155 773
MCR cap	R0320	70 098
MCR floor	R0330	38 943
Combined MCR	R0340	70 098
Absolute floor of the MCR	R0350	3 600

		C0070
Minimum Capital Requirement	R0400	70 098

Annex II - S.28.02.01

Minimum capital Requirement - Both life and non-life insurance activity

		Non-life activities	Life activities		Non-life activities	Life activities
		MCR(NL,NL) Result	MCR(NL,L) Result			
		C0010	C0020			
Linear formula component for non-life insurance and reinsurance obligations	R0010					

		Net (of reinsurance/ SPV) best estimate and TP calculated as a whole	Net (of reinsurance) written premiums in the last 12 months	Net (of reinsurance/ SPV) best estimate and TP calculated as a whole	Net (of reinsurance) written premiums in the last 12 months
		C0030	C0040	C0050	C0060
Medical expense insurance and proportional reinsurance					R0020
Income protection insurance and proportional reinsurance					R0030
Workers' compensation insurance and proportional reinsurance					R0040
Motor vehicle liability insurance and proportional reinsurance					R0050
Other motor insurance and proportional reinsurance					R0060
Marine, aviation and transport insurance and proportional reinsurance					R0070
Fire and other damage to property insurance and proportional reinsurance					R0080
General liability insurance and proportional reinsurance					R0090
Credit and suretyship insurance and proportional reinsurance					R0100
Legal expenses insurance and proportional reinsurance					R0110
Assistance and proportional reinsurance					R0120
Miscellaneous financial loss insurance and proportional reinsurance					R0130
Non-proportional health reinsurance					R0140
Non-proportional casualty reinsurance					R0150
Non-proportional marine, aviation and transport reinsurance					R0160
Non-proportional property reinsurance					R0170

Annex II - S.28.02.01

Minimum capital Requirement - Both life and non-life insurance activity

	Non-life activities		Life activities	
	MCR(L,NL) Result	MCR(L,L) Result		
	C0070	C0080		
Linear formula component for life insurance and reinsurance obligations			R0200	

	Net (of reinsurance/SPV) best estimate and TP calculated as a whole		Net (of reinsurance/SPV) total capital at risk	
	Net (of reinsurance/SPV) best estimate and TP calculated as a whole	Net (of reinsurance/SPV) total capital at risk	Net (of reinsurance/SPV) best estimate and TP calculated as a whole	Net (of reinsurance/SPV) total capital at risk
	C0090	C0100	C0110	C0120
Obligations with profit participation - guaranteed benefits	R0210			
Obligations with profit participation - future discretionary benefits	R0220			
Index-linked and unit-linked insurance obligations	R0230			
Other life (re)insurance and health (re)insurance obligations	R0240			
Total capital at risk for all life (re)insurance obligations	R0250			

Annex II - S.28.02.01

Minimum capital Requirement - Both life and non-life insurance activity

2

		C0130
Linear MCR	R0300	
SCR	R0310	
MCR cap	R0320	
MCR floor	R0330	
Combined MCR	R0340	
Absolute floor of the MCR	R0350	

		C0130
Minimum Capital Requirement	R0400	

Notional non-life and life MCR calculation

		Non-life activities	Life activities
		C0140	C0150
Notional linear MCR	R0500		
Notional SCR excluding add-on (annual or latest calculation)	R0510		
Notional MCR cap	R0520		
Notional MCR floor	R0530		
Notional Combined MCR	R0540		
Absolute floor of the notional MCR	R0550		
Notional MCR	R0560		